Document:

EX-10.20

 Exhibit 10.20 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
 MANUFACTURING AND SUPPLY AGREEMENT 

This Manufacturing and Supply Agreement (“Agreement”) is entered into as of September 18th, 2013 (“Effective Date”) by and between ViewRay Incorporated, a Delaware corporation (“ViewRay”), and Japan Superconductor Technology, Inc., a
corporation organized under the laws of Japan (“Jastec”). ViewRay and Jastec may each be referred to hereafter as a “party” or collectively as the “parties.” 

Background 
 ViewRay possesses valuable
knowledge, expertise, intellectual properties and resources with regard to high performance radiation oncology devices. Jastec possesses valuable knowledge, expertise, intellectual properties and resources with regard to the fabrication of
superconducting magnets for imaging applications. 
 ViewRay wishes to engage Jastec manufacture and supply it with a superconducting magnet that meets
certain agreed technical specifications for incorporation into ViewRay’s MRI-guided radiation therapy system. Jastec is willing to manufacture and supply ViewRay quantities of such magnets. 

NOW THEREFORE, in consideration of the mutual promises contained in this Agreement, and for other good and valuable consideration, the receipt, adequacy and
sufficiency of which are hereby acknowledged, the parties agree as follows: 
 1. DEFINITIONS. 

1.1 Defined Terms. Capitalized terms used in this Agreement and not otherwise defined herein shall have the meaning set forth below. 

“Affiliate” means with respect to either party, any Person that, directly or indirectly, is controlled by, controls or
is under common control with such party. For purposes of this definition only, “control” means, with respect to any Person, the direct or indirect ownership of more than fifty percent (50%) of the voting or income interest in such
Person or the possession otherwise, directly or indirectly, of the power to direct the management or policies of such Person. 

“Applicable Laws” means all applicable laws, statutes, regulations and ordinances. 

“ATP” means the manufacturing acceptance testing procedures developed by Jastec during the Program as approved by
ViewRay. The ATP shall be based upon the acceptance testing procedures used by ViewRay and [***] for the current magnet that are included in the TDP (defined below). Following such approval, the ATP will be attached to this Agreement as
Attachment 3. 
 “Business Day” means any day other than a Saturday or Sunday that is not a
national holiday in the United States or Japan. 
 “Commercially Reasonable Efforts” means with respect
to any objective by either party, commercially reasonable, diligent, good faith efforts to accomplish such objective as such party would normally use to accomplish a similar objective under similar circumstances. 

“Confidential Information” means any proprietary or confidential information (including but not limited to all ViewRay
Intellectual Property and all Jastec Intellectual Property) disclosed by either party to the other party (a) pursuant to this Agreement; or (b) pursuant to the Nondisclosure Agreement between the parties dated February 5th, 2013; in
each case provided the information in question is marked as confidential or proprietary, or, if disclosed orally or visually, identified as confidential or proprietary at the time of disclosure and confirmed as such in a written summary delivered to
the receiving party within a reasonable time thereafter, and except any portion thereof which: (i) is known to the receiving party, as evidenced by the receiving party’s prior written records, before receipt thereof; (ii) is disclosed
to the receiving party by a third Person who is under no obligation of confidentiality to the disclosing party hereunder with respect to such information and who otherwise has a right to make such disclosure; (iii) is or becomes generally known
in the public domain through no fault of the receiving party; or (iv) is independently developed by the receiving party, as evidenced by the receiving party’s written records, without access to such information. 

 “FCA” means “Free Carrier (named place)”, as that
expression is defined in Incoterms 2000, ICC Publishing S.A. 
 “Intellectual Property Right(s)” means
all rights in (1) U.S. and foreign utility and/or design patents, patent applications, and utility models; (2) patents issuing on the patent applications described in clause (1); (3) continuations, continuations-in-part, divisions,
reissues, reexaminations, or extensions of the patents or applications described in clauses (1)-(2); (4) inventions, invention disclosures and improvements, whether or not patentable; (5) works of authorship, whether or not protectable by
copyright, all copyrights to such works, including all copyright registrations and applications and all renewals and extensions thereof; (6) rights in industrial designs, and (7) Confidential Information, trade secrets, know-how,
processes, algorithms, proprietary databases, and other proprietary information, and all tangible and intangible embodiments thereof. 

“Jastec Intellectual Property” means, individually and collectively, all Intellectual Property Rights that are
conceived, discovered, developed, generated, created, made or reduced to practice or fixed in a tangible medium of expression solely by employees or consultants of Jastec at any time prior to the Effective Date or after the Effective Date if such
Intellectual Property Rights are not based upon or related to the performance of the Program. The term Jastec Intellectual Property, however, does not include any know-how, processes, information and data not otherwise protected by patent,
copyright, or other registrations, which is, as of the Effective Date or later becomes, generally available to the public through no breach by ViewRay of its obligations under this Agreement. 

“Person” means any individual, corporation, association, partnership (general or limited), joint venture, trust, estate,
limited liability company, limited liability partnership, unincorporated organization, government (or any agency or political subdivision thereof) or other legal entity or organization. 

“Product” means the split coil, superconducting magnet that can be incorporated in the MRI subsystem of the ViewRay MRI
guided radiation therapy system that will be manufactured by Jastec for ViewRay in accordance with this Agreement. The Product will be based upon the Specifications. 

“Program” means the manufacturing program for the initial unit of Product described in Attachment 1. 

“Program Intellectual Property” means, individually and collectively, all Intellectual Property Rights that are
conceived, created, discovered, developed, generated, made or reduced to practice or fixed in a tangible medium of expression as part of or based upon or related to activities undertaken as part of a Program whether: (a) solely by one or more
employees or agents of Jastec; (b) solely by one or more employees or agents of ViewRay; or (c) jointly by one or more employees or agents of Jastec and one or more employees or agents of ViewRay. 

“Spare Parts” means spare parts or components for the Products. 

“Specifications” or “Product Specifications” means the specifications for the Product set forth
in technical specification document TS1554C attached as part of Attachment 1, as they may be amended by the parties in accordance with Section 2.4. 

“TDP” or “Technical Data Package” means the technical data package for the split coil,
superconducting magnet that is currently being manufactured for ViewRay by [***] for use in the ViewRay MRI Guided Radiation Therapy System. The TDP includes, detailed mechanical drawings, assembly drawings, component specification drawings, bill of
materials, electrical schematics, assembly drawings, specifications relating to all of the foregoing (including the Specifications), and the acceptance test procedures used by ViewRay and [***] for such magnet. 

“ViewRay Intellectual Property” means, individually and collectively, all Intellectual Property Rights that are
conceived, discovered, developed, generated, created, made or reduced to practice or fixed in a tangible medium of expression solely by employees or consultants of ViewRay at any time prior to the Effective Date or after the Effective Date if such
Intellectual Property Rights are not based upon or related to the performance of the Program. The term ViewRay Intellectual Property, however, does not include any know-how, processes, information and data not otherwise protected by patent,
copyright, or other registrations, which is, as of the Effective Date or later becomes, generally available to the public through no breach by Jastec of its obligations under this Agreement. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 1.2 Other Defined Terms. The following terms shall have the meanings set forth in the Section appearing
opposite such term: 
  

			
	 “Acceptance”
	  	Section 2.3
	 “AER”
	  	Section 4.4
	 “[***]”
	  	Section 2.1
	 “Agreement”
	  	Recitals
	 “Applicable Standards”
	  	Section 4.1
	 “Bankruptcy Code”
	  	Section 5.1
	 “Change Control Document”
	  	Section 2.4
	 “Deliverable”
	  	Section 2.3
	 “disadvantaged party”
	  	Section 10.14
	 “Effective Date”
	  	Recitals
	 “FDA”
	  	Section 4.1
	 “Force Majeure”
	  	Section 10.14
	 “Forecast”
	  	Section 3.2
	 “Indemnifying Party”
	  	Section 8.4
	 “Initial Term”
	  	Section 9.1
	 “Jastec”
	  	Recitals
	 “Jastec Indemnified Party(ies)”
	  	Section 8.3
	 “Losses”
	  	Section 8.2
	 “MDR”
	  	Section 4.4
	 “Purchase Order”
	  	Section 3.3
	 “Reference Exchange Rate”
	  	Section 3.5
	 “Regulatory Authority”
	  	Section 4.1
	 “Renewal Term”
	  	Section 9.1
	 “RMA”
	  	Section 3.7
	 “Rules”
	  	Section 10.2
	 “SOPs”
	  	Section 4.4
	 “TDP Update”
	  	Section 3.10
	 “Term”
	  	Section 9.1
	 “ViewRay”
	  	Recitals
	 “ViewRay Indemnified Party(ies)”
	  	Section 8.2.

 2. PROGRAM FOR INITIAL UNIT 

2.1 Manufacture of Initial Units of Product. (a) The Program is directed toward the manufacture of a Product that conforms to the Specifications
(including the documents referenced therein). It is understood and agreed that Jastec will use its Commercially Reasonable Efforts to complete the Program and deliver a unit of Product that conforms to the Specifications on or before July 1,
2014. The Specifications are for the Product that is currently being manufactured and supplied to ViewRay by [***] (“[***]”). 
 (b) ViewRay shall
provide Jastec with the Technical Data Package for the Product as currently manufactured for ViewRay by [***]. Within fourteen (14) days after Jastec such Technical Data Package from ViewRay, Jastec will notify ViewRay whether or not Jastec is
able to produce the Product in accordance with the terms of this Agreement (including the attachments). If Jastec notifies ViewRay that it is unable to produce the Product then either party may terminate this Agreement with notice to the other party
delivered within two (2) Business Days after Jastec notifies ViewRay that it is unable to produce the Product. 
 (c) ViewRay shall also provide Jastec
with access to the ViewRay customer site where the installation and commissioning of the next ViewRay system embodying a Product supplied by [***] in order to permit Jastec technical personnel to familiarize themselves with the procedures followed
with respect to installation and commissioning of the Product in the field. 
 (d) ViewRay shall also seek to provide Jastec with access to the [***]
facility in [***] to permit Jastec to observe certain production steps for the Product as manufactured by [***], provided that it is expressly understood that ViewRay cannot cause [***] to provide such access and in the event and to the extent that
access is not provided, ViewRay and Jastec shall use Commercially Reasonable Efforts to engage appropriate [***] technical personnel (current or former) to provide consulting services to Jastec with respect to these production practices. 

(e) Each party shall provide such technical assistance as is reasonably requested by the other party and is also reasonably necessary for the timely and
complete performance of the Program responsibilities of such other party. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 2.2 Progress Reports. (a) ViewRay and Jastec shall periodically meet, in person or by telephone or
videoconference at such times and places as are mutually agreed upon, for Jastec to provide ViewRay with an update on the status of the progress of the Program. 

(b) While Jastec will make recommendations with respect to the design and manufacture of the Product, ViewRay shall exercise a broad general power of
supervision over the Product design, with final approval of the design and development of the Product (including, but not limited to, the definitive TDP). 

2.3 Deliverables. (a) Jastec will provide ViewRay with reasonable access at the Jastec facility during regular business hours to each deliverable
due under Attachment 1 (each, a “Deliverable”) in accordance with the schedule in Attachment 1; provided that those Deliverables that can be reasonably provided to ViewRay
electronically shall be delivered in that medium. After “delivery”, ViewRay shall inspect the Deliverable and test such Deliverable against the Specifications using the ATP. If ViewRay accepts the Deliverable, ViewRay shall acknowledge its
acceptance (“Acceptance”) of the Deliverable in writing. If ViewRay rejects the Deliverable, ViewRay shall provide Jastec with notice of rejection, including a reasonably specific description of the failure alleged. The
parties shall confer and agree upon a plan to resolve the nonconformity with the Specifications and a budget for such efforts and Jastec will use Commercially Reasonable Efforts to cure any such deficiencies as soon as possible and redeliver such
Deliverable to ViewRay. ViewRay shall have ten (10) Business Days following its receipt of the redelivered Deliverable in which to accept or reject the Deliverable. The parties shall repeat the above process until the earlier of the date the
Deliverable complies with the applicable Specifications or until ViewRay notifies Jastec that it is unwilling to continue to fund its portion of remediation costs with respect to a proposed remediation plan; provided that such notice shall not be
delivered until after completion of the initial remediation plan for the Deliverable and shall not be delivered during the time period when Jastec is performing an approved remediation plan for such Deliverable. 

(b) It is understood and agreed that the Deliverables need not be error-free to have achieved the requirements for ViewRay to make payment of the milestones
specified in Attachment 2, but if any Deliverable delivery or redelivery contains errors that individually or in the aggregate adversely affect ViewRay’s ability to use such Deliverable in accordance with the Specifications
or embodies defects in materials or workmanship, ViewRay may rightfully reject such Deliverable delivery or redelivery. Notwithstanding the foregoing, Acceptance will not relieve Jastec of its obligation to use Commercially Reasonable Efforts to fix
all identified errors in a timely fashion. 
 (c) ViewRay will use Commercially Reasonable Efforts to test each Deliverable as quickly as practicable and in
any event within thirty (30) days of delivery of such Deliverable. 
 2.4 Changes. (a) During the Program, either party may request
amendments to Attachment 1 to effect changes in the Specifications or may request changes in the TDP. If either party wishes to make a change it shall notify the other party of the requested change specifying the change
with sufficient details to enable the other party to evaluate it. The parties shall promptly confer regarding the proposed change and assess (i) the impact of the change on the schedule, (ii) the impact of such change on the cost for the
Product, and (iii) the impact of such change on the technical risk of the Programs. The parties shall attempt to resolve any disagreement with respect to whether a proposed change should be undertaken or not but in the event of a disagreement
with respect to whether or not to adopt and implement a proposed change ViewRay shall have the final decision except with respect to the cost of implementing such change, which must be mutually agreed in accordance with Section 2.6. 

(b) The parties shall enter into a written change control document documenting any change adopted pursuant to this Section 2.4 including the technical
details of such change, the expected impact of such change on the schedule and the budgeted costs for such change (a “Change Control Document”). Jastec shall not implement any proposed change without a Change Control
Document. ViewRay shall be responsible for preparing each Change Control Document and Jastec shall enter into such Change Control Document promptly upon presentation by ViewRay. 

2.5 Success Criteria. If the initial unit of Product conforms to the Specifications, then the provisions of Section 3 shall take effect. If the
initial unit of Product does not conform to the Specifications or if ViewRay and Jastec determine during the course of the Program that the results of the Program are unsatisfactory; which determination shall be made with reference to the prospects
for realizing Products that meet the Specifications then in each case they may mutually agree to terminate the Program under Section 9.2(d). If the parties do not agree with respect to termination of the Program pursuant to this
Section 2.5, they shall resolve such dispute using the procedure specified in Section 10.2(a)-(b). 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 2.6 Program Funding. Recognizing that (a) the manufacture of the initial unit of Product is a
developmental activity (and that there are uncertainties attendant thereto) and (b) the initial three (3) units of Product will be ordered by ViewRay prior to the date that the initial unit of Product is completed in order to facilitate
delivery of the second unit of Product by mid-October 2014 and the delivery of the third unit of Product by mid-November 2014, the price for the initial three (3) units of Product have been adjusted upwards based upon Jastec’s estimate as
of the Effective Date of the costs for the performance of the Program. If, however, additional costs are necessary for the completion of Product unit 1, 2 or 3 based upon Jastec having an incomplete understanding of the manufacturing process for the
Product prior to the completion of the Program with respect to the initial unit of Product, then the parties shall follow the procedure specified in Section 2.4 with respect to the additional costs required to complete Product unit 1, 2 or 3
and such additional costs shall be borne 50% each by the parties. The parties shall attempt to schedule the manufacture of each of the initial three units of Product in a manner that reduces the risk that the second and third units of Product are
advanced to a production stage until the initial unit of Product has cleared that stage successfully. 
 3. PURCHASE OF PRODUCTS AND TERMS OF SALE

 3.1 Supply. If the initial unit of Product conforms to the Specifications then ViewRay may place Purchase Orders for Products or Spare Parts
from time to time during the Term at prices specified in Section 3.5. 
 3.2 Purchase Forecasts. ViewRay will deliver to Jastec a non-binding
twenty four (24) month rolling forecast (the “Forecast”). The Forecast will cover the 24 months commencing with and including the calendar month in which the first delivery of Products is to occur. After delivery of the initial
Forecast, the Forecast will be updated on a quarterly basis. 
 3.3 Product Orders. (a) ViewRay will submit to Jastec firm written purchase
orders (each a “Purchase Order”) for the purchase of Products at least ten (10) months prior to the specified delivery date of the ordered Products for units of Product after unit 6 and at least twelve (12) months
prior to the specified delivery date of the ordered Products for the initial 6 units of Product. Each Purchase Order will specify the quantity or, if more than one shipment is requested, quantities of Products ordered, the requested delivery date or
dates, and ship-to locations. Orders will be placed by ViewRay to Jastec by email or facsimile, or by other means agreed upon by the parties, to an address provided by Jastec, which will initially be, [***]. In the case of conflict between the
provisions of this Agreement and either the standard printed terms of any Purchase Order or the standard printed terms of sale of Jastec, the provisions of this Agreement will control. 

(b) ViewRay may delay shipment for up to six (6) months with notice to Jastec delivered at least thirty (30) days prior to the scheduled delivery
date. ViewRay may cancel Purchase Orders with notice of cancellation delivered at least thirty (30) days prior to the scheduled delivery date; provided that ViewRay reimburses Jastec for the materials purchased within the established materials
lead time and for the labor costs incurred within the established labor lead time in respect of such cancelled Purchase Order and provided further that no reimbursement shall be due Jastec if ViewRay continues to submit Purchase Orders to Jastec for
Products. 
 3.4 Obligation to Supply. (a) Jastec will acknowledge all Purchase Orders within five (5) Business Days following receipt of
same and will accept and fill each order for Product submitted by ViewRay within ten (10) months following the date such Purchase Order is received for units of Product after unit 6 and within twelve (12) months following the date such
Purchase Order is received for the initial 6 units of Product, including orders that exceed the Forecast for any month by up to fifty percent (50%) of the amount in the Supply Forecast for such month delivered ten (10) months prior to such
month with respect to orders for Product after unit 6 and twelve (12) months prior to such month with respect to orders for the initial 6 units of Product. Jastec will not be in breach of this Section 3.4 if Jastec’s failure to supply
Products is due to a Force Majeure event or if Jastec’s failure is limited to quantities in excess of the quantities specified in this Section 3.4. 

(b) Each party will promptly notify the other party of any circumstances that it believes may be of importance as to Jastec’s ability to meet
ViewRay’s needs for the Products in a timely manner. If the Forecasts indicate that ViewRay’s need for the Products will exceed Jastec’s existing capacity to supply the Products, the parties will determine in good faith whether Jastec
successfully can expand its production capacity so as to meet ViewRay’s needs in a timely manner. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (c) Jastec will use Commercially Reasonable Efforts to meet all committed delivery dates for Product and to
achieve better than ninety five percent (95%) on-time delivery performance. For purposes of this Section 3.4(c) Product delivery shall be on-time if the delivery is made by: (i) the committed delivery date specified in Section 3.3(a)
or up to thirty (30) days earlier than the committed delivery date specified in Section 3.3(a) for the initial 4 units of Product; and (ii) the committed delivery date specified in Section 3.3(a) or up to fourteen (14) days
earlier than the committed delivery date specified in Section 3.3(a) for all subsequent units of Product. Commencing with the delivery of Product unit 5 a Product delivery shall be deemed late if it is delivered more than thirty (30) days
after the committed delivery date specified in Section 3.3(a), and there shall be a price reduction on such late deliveries equal to two percent (2%) of the purchase price of the units of Product that are delivered late. Jastec shall
reflect such price reduction, if possible, in its invoice to ViewRay for the applicable Product units. In the event Jastec is unable to reflect such price reduction in such invoice, ViewRay shall be entitled to deduct the amount of the price
reduction from any invoice due to Jastec, including the invoice submitted by ViewRay for the applicable Product units. Delivery of a partially completed Product, or a Product that does not conform to the Specifications, shall be counted as a late
delivery. If ViewRay requests Jastec to deliver a unit of Product with a lead-time shorter than specified in Section 3.3(a), and Jastec agrees to said earlier delivery date, then no price reduction shall apply to such unit of Product under this
Section 3.4(c) until the late period extends beyond the lead-time specified in Section 3.3(a). 
 3.5 Pricing.
(a) ViewRay shall pay Jastec the prices set forth in Attachment 2 for the Products, Spare Parts and installation and support services provided by Jastec to ViewRay pursuant to this this Agreement. ViewRay acknowledges that
Jastec has not received the TDP from [***] and that accordingly certain materials costs and other design considerations are unknown by Jastec. The pricing set forth in Attachment 2 is acknowledged as a best estimate, but will be
confirmed by Jastec within thirty (30) days of Jastec’s receipt of the TDP. ViewRay has provided an estimated purchase price of direct materials for the Bill of Materials used in the existing magnet supplied ViewRay by [***] in the amount
of $[***] (including [***] costs for Product testing at the Jastec facility but excluding [***] costs at the ViewRay customer site) for purposes of Jastec preparing their Product pricing specified in Attachment 2. If the actual
purchase price for the direct materials for the Bill of Materials exceeds $[***] based upon Jastec’s review of the [***] TDP, then the Product pricing set forth in Attachment 2 shall be adjusted so that the pricing provides
Jastec with [***]% overhead on materials and a [***]% profit margin on the Product. 
 (b) All payments will be made by wire transfer. Jastec will
invoice ViewRay and ViewRay shall pay Jastec in installments as set forth in Attachment 2. 
 (c) If ViewRay fails to make any payment
due to Jastec under this Agreement by the due date for payment, then, without limiting Jastec’s remedies under Section 1 0.2, the overdue amount shall accrue interest at the rate of 1.5% per annum above LIBOR (as published as of the
closing of markets on the due date) from the due date until the date of actual payment of the overdue amount. This Section 3.5(c) shall not apply to payments that ViewRay contests in good faith using the procedures in Section 10.2 during
the pendency of such dispute; provided that in the event ViewRay does not prevail in such dispute then interest shall accrue from the date payment was due until the date ViewRay makes payment and such payment shall when made shall be
accompanied by all interest so accrued. 
 (d) All payments shall be stated and paid in U.S. Dollars. If the exchange rate for purchasing Japanese Yen with
U.S. Dollars as stated in the Wall Street Journal, New York edition increases or decreases by more than ten percent (10%) from the rate of I U.S. Dollar to 100 Japanese Yen (the “Reference Exchange Rate”) on the date
ViewRay places a Purchase Order for Product, then the parties shall adjust the prices set forth in Attachment 2 to reflect such increase or decrease, as applicable; so that the adjustment is shared equally (50% each) by ViewRay and
Jastec. Such revised price shall become the new Reference Exchange Rate, for purposes of calculating future increases or decreases of more than ten percent (10%), shall be set at that of the then-prevailing exchange rate. 

(e) Jastec acknowledges that ViewRay must continually reduce the price of the ViewRay system to increase the sales of such system and that this requires that
Jastec and ViewRay develop cost reduction strategies for the Product. Within ninety (90) days following the Effective Date and at least quarterly thereafter, Jastec and ViewRay will confer to identify and implement cost reductions. Specific
cost reduction projects mutually agreed will be effective immediately upon implementation into the manufacturing process and will be reviewed periodically and mutually agreed to by ViewRay and Jastec. Cost reductions developed and proposed by
ViewRay shall reduce the price of the Product by an amount equal to the actual reduction in the cost of goods for the Product including an amount representing the materials overhead allocable to such cost of goods reduction and the profit
margin allocable to such cost of goods reduction). Cost reductions developed and proposed by Jastec and cost reductions developed and proposed jointly by the parties shall reduce the price of the Product [***] for the Product and [***]
representing [***]. If a cost reduction opportunity requires a capital investment, Jastec and ViewRay will [***]. The parties shall follow the procedure specified in Section 2.4 with respect to reviewing and approving changes pursuant to
this Section 3.5. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 3.6 Shipping. Jastec shall arrange for shipment and invoicing to ViewRay of the Products ordered by
ViewRay via common carrier, FCA Jastec’s Kobe facility. Unless otherwise stated in the applicable Purchase Order, Jastec will be exporter of record and ViewRay will be importer of record for shipments requiring export from the United States.
Jastec will provide itemized invoicing for any additional logistics services as agreed between the parties. 
 3.7 Acceptance; Defective Product.
(a) Jastec shall perform all in-process and finished Product tests required by the Product Specifications and the TDP, including the factory acceptance test detailed in the ATP (when available), and any additional quality control tests as
mutually agreed from time-to-time. All such tests and test results shall be performed, documented and summarized by Jastec in accordance with the Product Specifications. Jastec shall promptly notify ViewRay of any out-of-specification test results
for either in-process or finished Product. Each shipment of Product from Jastec to ViewRay shall contain such quality control certificates as are necessary to show that the Product is in conformity with the Product Specifications. Upon installation
of the Product by ViewRay at the ViewRay customer site, ViewRay shall test the Product against the Product Specifications and notify Jastec whether or not the Product conforms to the Product Specifications. 

(b) Jastec will at its own expense and at no further cost to ViewRay repair or replace Products that do not conform to the applicable warranties specified in
Section 7.2 during the applicable warranty period specified therein using the procedure specified in this Section 3.7. ViewRay will notify Jastec in writing of any alleged defect of Product and based upon the nature of the alleged defect,
will either request a Return Material Authorization (“RMA”) number from Jastec or request that Jastec dispatch service personnel to inspect the applicable Product in the field. If ViewRay requests that Jastec dispatch service
personnel, Jastec shall dispatch such service personnel within two (2) days. If ViewRay requests a RMA number then Jastec shall within twenty-four hours issue an RMA number and will promptly coordinate with ViewRay to arrange for the removal of
such Product from its installed site and return of such Product to Jastec. Jastec will pay the cost of all shipping, rigging, installation, commissioning and cryogens required for removal and replacement of such Product. Jastec will use Commercially
Reasonable Efforts to deliver repaired or replacement Product to the ViewRay customer facility freight prepaid and properly insured with earliest delivery that can be obtained. In the event that Jastec reasonably determines that any allegedly
nonconforming Product is in fact not defective (including Product that has been modified, misused, abused or the subject of unauthorized repair by a party other than ViewRay), Jastec will notify ViewRay in writing and ViewRay will reimburse Jastec
for all reasonable costs and expenses related to the inspection, the cost of the replacement Product (if any), and the cost of the return of such Product to ViewRay (if applicable). If ViewRay disputes Jastec’s determination that a Product is
not defective, the dispute will be discussed and resolved using the procedure provided in Section 10.2. 
 3.8 Jastec Product Support. ViewRay will
provide ViewRay service and support to its customers for the ViewRay system incorporating the Product. During the Term, Jastec will (a) provide on-site support for ViewRay’s installation for the initial [***] units of Product and
(b) upon ViewRay’s request provide telephonic, email and (if requested by ViewRay) on-site engineering support services to ViewRay (and not to ViewRay customers) for Products that are the subject of failures in the field. The pricing for
such support services are set forth in Attachment 2. 
 3.9 Spare Parts. Jastec will inventory a mutually agreed list of spare
parts for the Product in sufficient quantities and at appropriate locations to permit ViewRay to deliver front line support to the ViewRay customers at a 98% availability rate and within 4 hours of notification of a failure of the Product. Jastec
will enter into appropriate agreements with key OEM suppliers where possible to develop repair/refurbish programs for applicable high value parts, modules or field replaceable assemblies for Product. In order to maximize service levels to the
customer and minimize inventory levels cycle times of processes such as repair and return of material need to be as low as possible. 
 3.10 Corrective
Action Plan. (a) If Jastec fails to supply Product ordered by ViewRay in accordance with Section 3.3, then Jastec shall within [***] of said failure present ViewRay with a plan to remedy the problem and shall use Commercially Reasonable
Efforts to execute such plan and remedy the problem. If Jastec is unable to remedy the problem within [***] after its initial failure to supply, then Jastec shall consult with ViewRay and the parties shall work together to remedy the problem. If
Jastec is unable to remedy the supply problem after an aggregate period of [***] (or longer as agreed in writing by the parties), commencing with the date upon which such failure to supply began, then ViewRay may at its option, and upon notice to
Jastec, terminate this Agreement. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (b) If ViewRay notifies Jastec that ViewRay will terminate this Agreement in accordance with
Section 3.10(a), then Jastec shall (i) cooperate with ViewRay to cause the release of the then most recent TDP, including any changes to the TDP from the then most recent update provided ViewRay pursuant to Section 3.10(c)); and
(ii) provide ViewRay or its designee, upon request, with reasonable assistance in establishing a manufacturing line. ViewRay shall pay Jastec’s reasonable travel and living expenses in providing such assistance. ViewRay shall require any
third party ViewRay designates to manufacture Products to agree in writing to observe the terms of this Agreement relating to confidentiality and the use of Jastec Intellectual Property. 

(c) Jastec shall deliver to ViewRay in accordance with Attachment 1 an updated TDP for the Product containing all information necessary
or useful for ViewRay or its designee to manufacture Products conforming with the Specifications (and any enhancements, modifications, upgrades, corrections, and components to the Product developed during the term of this Agreement), including any
detailed mechanical drawings, assembly drawings, component specification drawings, assembly drawings, electrical schematics, manufacturing instructions, testing equipment vendors (and detailed modification notes for any modifications made to such
testing equipment for purposes of testing the Products) equipment settings, supply chain information, costed bills of materials, testing procedures, or other information as well as any manuals, programmers notes, and other materials needed to access
and use such materials (collectively, the “TDP Update”). Jastec shall maintain the TDP Update and provide ViewRay on an annual basis with a written copy any changes in the TDP Update. 

4. QUALITY ASSURANCE; SUPPORT 
 4.1 Manufacturing
Practices; Testing. Jastec shall manufacture the Products in accordance with the Specifications. Jastec will install and maintain effective quality control systems, conduct quality assurance testing and keep comprehensive process control records
conforming to ( 1) appropriate best practices, including the then applicable good manufacturing practices regulations of the U.S. Food and Drug Administration (“FDA”) under 21 C.F.R. Part 820 or comparable regulations of any
other supra-national, regional, federal, state, or local regulatory agency or authority that has authority to grant registrations, authorizations, licenses and approvals necessary for the commercial manufacture, distribution, marketing, promotion,
sale, use, importation, or exportation of the Products (each, including the FDA, a “Regulatory Authority”) that apply to the manufacture of the Product (“Applicable Standards”) including specifically
ISO 9001 certification and ISO 13485 certification (which may be used in lieu of 21 C.F.R. Part 820); and (3) other requirements set forth herein. It is understood that Jastec does not currently hold ISO 13485 certification, but Jastec shall
use Commercially Reasonable Efforts to obtain ISO 13485 certification. 
 4.2 Regulatory Clearances. ViewRay will have sole responsibility and
authority for obtaining and maintaining regulatory clearance of the ViewRay system incorporating the Product (and all improvements or variations to such ViewRay system incorporating the Product developed during the term of this Agreement), including
without limitation obtaining and maintaining approvals and clearances from the FDA and any other Regulatory Authority necessary for the ViewRay system incorporating the Product or the commercial distribution and sale of the ViewRay system
incorporating the Product. All regulatory filings with the FDA or any other Regulatory Authority relating to the ViewRay system incorporating the Product will be made in the name of ViewRay or its designee and ViewRay will be responsible for
maintaining the required records for such system. 
 4.3 Quality Assurance Inspections. (a) During regular business hours and upon reasonable
advance notice and in a manner that does not disrupt or interfere with the business of Jastec, Jastec will permit ViewRay and its agents to inspect the facilities of Jastec, pertaining to the Products and provide access to Jastec’s
manufacturing quality control documentation related to the Products to the extent necessary for, and for the purpose of assessing Jastec’s compliance with this Agreement. As a condition of provision to ViewRay agents of access to Jastec’s
facilities and documentation, all information obtained by ViewRay agents as a result of such access will be Jastec Confidential Information for purposes of this Agreement. Jastec may require any agent of ViewRay seeking access to Jastec’s
facilities under this Section 4.3(a), as a condition to such access, to execute a standard confidentiality agreement with Jastec under which such agent agrees to treat information disclosed during such inspection as the Confidential Information
of Jastec under terms and conditions no less restrictive than the terms contained in Section 6.2. 
 (b) Jastec will allow representatives of the FDA
or any other Regulatory Authority with jurisdiction over the manufacture, marketing, distribution and sale of the Products to tour and inspect the facilities utilized by Jastec in the manufacture of the Product, and will cooperate with such
representatives in every reasonable manner. Jastec 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
will promptly (within twenty four (24) hours) provide ViewRay notice of all inspections of Jastec’s facilities by inspectors of the FDA or any other Regulatory Authority reasonably
related to its performance hereunder or the subject matter of this Agreement and will permit ViewRay to attend such inspections. Jastec will provide ViewRay with copies of any notices of adverse findings, regulatory letters or similar writings it
receives from any Regulatory Authority setting forth adverse findings or non-compliance with Applicable Laws, regulations or standards relating to the Products supplied by Jastec hereunder within two (2) working days of its receipt thereof, and
Jastec’s written response to such Regulatory Authority not later than the date of its submission thereof. 
 (c) If an inspection pursuant to
Section 4.3 (a) reveals that the facilities used to manufacture Products do not satisfy the Applicable Standards in all material respects, then ViewRay will promptly provide to Jastec written notice of such fact, which notice will contain
in reasonable detail the deficiencies found in the manufacturing facilities and, if practicable, those steps ViewRay believes Jastec should undertake in order to remedy such deficiencies. Jastec will remedy such deficiencies within a reasonable
period of time after receipt of such written notice and provide evidence of this corrective action to ViewRay as requested. 
 (d) Jastec will maintain
manufacturing quality documentation and will certify that Product was manufactured and tested in accordance with the Specifications and Applicable Standards. ViewRay may request copies of such certifications as part of the inspections permitted
under Section 4.3(a). 
 (e) Jastec will comply with the Specifications and Applicable Standards in its manufacturing of the Products. Prior to
shipping any Product, Jastec will carry out the Product tests specified in the applicable Specifications on each unit of Product. If a Product or any part of a Product fails to meet the Specifications, the Product will be repaired or replaced by
Jastec as set forth in Section 7.3 and the relevant test will be repeated until such Product passes such test requirements. No Product will be shipped to ViewRay or its designee without passing all tests specified in the Specifications.
Certification of conformance and/or test reports will be provided on request with each unit as evidence of compliance. 
 4.4 Recalls.
(a) ViewRay will provide Jastec with ViewRay’s standard operating procedures (“SOPs”) as to recalls. If either party becomes aware of information about any Product indicating that it may not conform to the
Specifications, it will promptly so notify the other party. The parties will promptly confer to discuss such circumstances and to consider appropriate courses of action, which courses of action will be consistent with the SOPs. ViewRay will have the
right to initiate, and will bear all costs associated with, a recall, withdrawal, or field correction of the ViewRay system incorporating the Product for any reason; provided that ViewRay may proceed against Jastec pursuant to
Section 7.3 if such recall, withdrawal, or field correction of the ViewRay system incorporating the Product is the direct result of (i) any breach by Jastec of its duties under the Agreement or (ii) Jastec’s negligence or willful
misconduct. 
 (b) With respect to any recall, withdrawal, or field correction of a Product incorporated in a ViewRay system, ViewRay or its designee will
be responsible for coordinating all of the necessary activities in connection with such recall, withdrawal, or field correction. ViewRay and Jastec will coordinate any statements to customers and the media, including, but not limited to, press
releases and interviews for publication or broadcast and neither party will issue any such statements without consulting with the other and neither party shall identify the other party in any such statements without the other party’s written
consent, not to be unreasonably withheld, except as required by a Regulatory Authority. The parties will reasonably cooperate with each other in the conduct of such activities and will perform any acts reasonably requested by the other party to
facilitate the recall, withdrawal or field correction. Each party will keep the other party fully informed of progress and in relation to all material decisions or actions such party undertakes pursuant to this Section 4.4(b). 

(c) Each party will promptly (within two (2) working days unless a shorter time period is required under Applicable Law) notify the other party in
writing of any event or complaint that gives rise or could give rise to the need to file a Medical Device Report (an “MDR”) within the meaning of the Federal Food, Drug and Cosmetic Act of 1941, as amended or a similar report
under the laws or regulations administered by any Regulatory Authority (collectively, an “AER”), with respect to any Product or the manufacture, distribution or use thereof in accordance with the MDR regulation, 21 C.P.R.
Part 803 or similar regulations covering AER’s. Each such written notice will be Confidential Information under this Agreement. If, as a result of any corrective action or any final, non-appealable or
non-appealed governmental or court action, an AER is required to be issued for any Product sold hereunder, ViewRay will bear the costs and expenses of and will be responsible for all corrective actions
associated with such AER but may proceed against Jastec pursuant to Section 8.3 if such AER is the direct result of (i) any breach by Jastec of its duties under the Agreement or (ii) Jastec’s negligence or willful misconduct.

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 5. LICENSES; PROPRIETARY RIGHTS 

5.1 Jastec Licenses. (a) Jastec hereby assigns and agrees to assign to ViewRay title to all Deliverables and other work product that results from
Jastec’s performance of the Program, including any Program Intellectual Property Rights embodied in Deliverables or work product, whether such Program Intellectual Property Rights are owned solely by Jastec or jointly by Jastec and ViewRay.
ViewRay’s title in such Deliverables and work product and Program Intellectual Property shall not include any Jastec Intellectual Property embodied in such Deliverables or work product. Title to all such Jastec Intellectual Property shall
remain vested in Jastec and this Agreement does not convey to ViewRay any ownership rights in any portion of such Jastec Intellectual Property by implication, estoppel or otherwise. With respect to such Jastec Intellectual Property for which Jastec
retains title, Jastec hereby grants and agrees to grant to ViewRay a non-exclusive, worldwide, perpetual, paid-up and royalty-free license, including the right to grant sublicenses, to use such Jastec Intellectual Property owned by Jastec to the
extent necessary or useful for ViewRay to develop, make, have made, use, reproduce, prepare derivative works, modify, market, sell, distribute and import products and deliver services that embody or utilize the Products for medical applications.
ViewRay will not use Jastec Intellectual Property for any other purpose, without Jastec’s prior written permission. For the avoidance of doubt, it is understood and agreed that the license to use Jastec Intellectual Property granted under this
Section 5.1(a) includes the Jastec magnet shimming software and related documentation. 
 (b) The license granted under this Section 5.1 shall be
treated as a license of rights to “intellectual property” (as defined in Section I 01 (56) of Title 11 of the United States Code, as amended (the “Bankruptcy Code”)) for purposes of Section 365(n) of the
Bankruptcy Code. The parties agree that ViewRay may elect to retain and may fully exercise all of its rights and elections under the Bankruptcy Code provided, that it abides by the terms of this Agreement. 

5.2 ViewRay Licenses. (a) ViewRay hereby grants and agrees to grant to Jastec, solely to provide the applicable services under this Agreement and
to supply Products to ViewRay, a non-exclusive, paid-up and royalty-free license to use the ViewRay Intellectual Property and the Program Intellectual Property owned by ViewRay in connection with its performance of the Program and its supply of
Products. Upon the expiration or termination of this Agreement, Jastec’s license shall terminate and be of no further force or effect. 
 (b) ViewRay
hereby grants and agrees to grant to Jastec a non-exclusive, worldwide, perpetual, paid-up and royalty-free license, including the right to grant sublicenses, to use Program Intellectual Property with respect to which Jastec personnel are named as
inventors that is assigned to ViewRay in accordance with Section 5.1 to the extent necessary or useful for Jastec to develop, make, have made, use, reproduce, prepare derivative works, modify, market, sell, distribute and import products for
medical applications that are not competitive with the products sold by ViewRay. 
 5.3 Reservation of Rights. (a) This Agreement does not
convey to ViewRay any ownership rights in any portion of any Jastec Intellectual Property by implication, estoppel or otherwise, but constitutes only a license to use the Jastec Intellectual Property as necessary to give effect to the license and in
accordance with all of the terms of this Agreement. Title to the Jastec Intellectual Property shall at all times remain vested in Jastec. All rights in and to the Jastec Intellectual Property not expressly granted under this Agreement are reserved
to and retained by Jastec. 
 (b) This Agreement does not convey to Jastec any ownership rights in any portion of the ViewRay Intellectual Property or the
Program Intellectual Property owned by ViewRay by implication, estoppel or otherwise. Title to the ViewRay Intellectual Property and the Program Intellectual Property owned by ViewRay shall at all times remain vested in ViewRay. All rights in and to
the ViewRay Intellectual Property and the Program Intellectual Property owned by ViewRay not expressly granted under this Agreement are reserved to and retained by ViewRay. 

(c) Title to and any interest in Program Intellectual Property shall be the property of ViewRay and assigned to ViewRay in accordance with Section 5.1.

 (d) For purposes of this Agreement, except as otherwise set forth in this Agreement, the determination of as to which party invented any invention will
be made in accordance with the standards of inventorship and conception under title 35 of the U.S. Code and title 37 of the U.S. Code of Federal Regulations. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 6. CONFIDENTIALITY 

6.1 Publicity. The terms of this Agreement (including its existence) shall be treated as the Confidential Information of both parties and neither party
will issue any press release or make any other statement, written or oral, to the public, the press or otherwise, relating to this Agreement and the transactions contemplated by this Agreement that has not previously been approved in writing by the
other party. Nothing in this Section 6.1 shall prohibit a party from making such disclosures to the extent required under applicable federal or state securities laws or any rule or regulation of any nationally recognized securities exchange. In
such event, however, the disclosing party shall use good faith efforts to notify and consult with the other party prior to such disclosure and, where applicable, shall diligently seek confidential treatment to the extent such treatment is available
under applicable securities laws. Each party may provide a copy of this Agreement or disclose the terms of this Agreement: (a) to any finance provider in conjunction with a financing transaction, if such finance provider agrees to keep the
terms of this Agreement confidential, (b) to enforce its rights under this Agreement in a proceeding in accordance with Section 10.2, (c) to any legal or financial advisor of such party, or (d) to current/prospective investors
provided such investors are subject to a confidentiality agreement that is consistent with the terms of Section 6.2 regarding protection of Confidential Information of the other party. 

6.2 Confidentiality. (a) Confidential Information of each party will be used by the other party solely for the purposes permitted by this
Agreement. All Confidential Information of a disclosing party, will be received and held in confidence by the receiving party, subject to the provisions of this Agreement. Each party acknowledges that, except for the rights expressly granted under
this Agreement, it will not obtain any rights of any sort in or to the Confidential Information of the other party as a result of such disclosure and that any such rights must be the subject of separate written agreement(s). 

(b) Each party will restrict disclosure of the other party’s Confidential Information to those of its employees and consultants to whom it is necessary
or useful to disclose such Confidential Information in connection with the purposes permitted under this Agreement. Each party shall use reasonable efforts, including at least efforts commensurate with those employed by the party for the protection
of its own Confidential Information, to protect the Confidential Information of the other party. For the avoidance of doubt, it is understood and agreed that Jastec may provide Confidential Information of ViewRay pursuant to this Section 6.2
to: (i) representatives of its parent company Kobe Steel as necessary or useful to obtain research and development support and (ii) third party component suppliers as necessary or useful to obtain components for the manufacture of the
Product, provided such third party component suppliers are subject to a written confidentiality agreement containing terms consistent with the terms of this Section 6.2 with respect to the protection of the other party’s confidential
information. 
 (c) Nothing herein shall prevent a receiving party from disclosing all or part of the Confidential Information of the other party in
response to a court order or other legal proceeding requesting disclosure of same; provided, the party that receives such order or process provides prompt notice to the disclosing party before making any disclosure (to the extent possible)
and permits the disclosing party to oppose or narrow such request for disclosure and supports any of the disclosing party’s reasonable efforts to oppose such request (at disclosing party’s expense), and only to the extent necessary to
comply with such request. Disclosure of Confidential Information pursuant to this Section 6.2(c) will not alter the character of that information as Confidential Information hereunder. 

7. REPRESENTATIONS AND WARRANTIES. 
 7.1 Authorization;
Enforceability. Each of ViewRay and Jastec represents and warrants to the other party that: (a) it is duly organized and validly existing under the laws of its jurisdiction of organization and has all requisite power and authority to enter
into this Agreement; (b) it is duly authorized by all requisite action to execute, deliver and perform this Agreement and to consummate the transactions contemplated hereby, and that the same do not conflict or cause a default with respect to
such party’s obligations under any other agreement; (c) it has duly executed and delivered this Agreement; and (d) it is authorized to disclose any and all Confidential Information made available to the other party pursuant to this
Agreement. 
 7.2 Products. (a) Jastec warrants to ViewRay that all Products supplied to ViewRay pursuant to this Agreement shall: (i) for
a period of eighteen (18) months from the date of the Product is commissioned following installation and satisfaction of the installation acceptance tests contained in the ATP at the ViewRay customer site in accordance with Section 3.7,
conform to the Specifications, (ii) be manufactured, labeled, packaged, stored and tested (while in the possession or control of Jastec) in accordance with the Specifications current as of the date of manufacture and the Applicable Laws and
regulations in relation to the manufacture and testing of the Product (including all Applicable Standards), and (iii) be free of defects in materials or workmanship. This warranty does not apply to any non-conformity of the Products in
the event and to the extent resulting from misuse, mishandling or storage in an improper environment in each case by any party other than Jastec or its agents. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (b) Jastec warrants to ViewRay that all Products shall be delivered free and clear of all liens and encumbrances.

 7.3 Remedy. In the event any Products purchased by ViewRay from Jastec fail to conform to the warranty set forth in Section 7.2 and Jastec
receives written notice of such nonconformity during the applicable warranty period, Jastec shall, at Jastec’s option, repair or replace the Products using the procedures set forth in Section 3.7(b). ViewRay shall notify Jastec of any such
nonconformity in accordance with Section 3.7(b). It is understood and agreed that the remedy set forth in this Section 7.3 shall be the sole and exclusive remedy for defects or non-conformances in a Product once its warranty period begins,
excepting only a party’s remedies with respect to third party claims arising pursuant to Sections 8.2-8.3. 
 7.4 Disclaimer. (a) EXCEPT
FOR THE WARRANTIES EXPRESSLY MADE IN SECTION 7.1 AND SECTION 7.2, NEITHER PARTY MAKES ANY OTHER REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED (WHETHER WRITTEN OR ORAL), INCLUDING, WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY OR ANY
WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO ANY MATTER WHATSOEVER, INCLUDING BUT NOT LIMITED TO, THE PRODUCTS. 
 (b) THE REPRESENTATIONS
A:t\D WARRANTIES OF EXTEND ONLY TO THE OTHER PARTY. NEITHER PARTY WILL BE LIABLE FOR ANY CLAIM OR DEMAND AGAINST SUCH OTHER PARTY BY A THIRD PARTY, EXCEPT TO THE EXTENT PROVIDED IN SECTIONS 8.2-8.3. 

8. RISK ALLOCATION 
 8.1 Limitation of Liability.
EXCEPT FOR BREACH OF CONFIDENTIALITY OBLIGATIONS UNDER SECTION 6.2, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER FOR ANY LOST PROFITS OR SAVINGS OR FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES IN
CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY, REGARDLESS OF WHETHER THE PARTIES HAVE ADVISED OR BEEN ADVISED OF THE POSSIBILITY OF ANY SUCH LOSS OR DAMAGE. 

8.2 Indemnification of ViewRay. Subject to the provisions of Section 8.4, Jastec will defend, indemnify, and hold harmless ViewRay and its
Affiliates, officers, directors, employees, agents, and their successors and assigns (each, in such capacity, an “ViewRay Indemnified Party”) from and against any claim, suit, demand, loss, damage, expense (including
reasonable attorneys’ fees of ViewRay Indemnified Party(ies) and those that maybe asserted by a third party) or liability (collectively, “Losses”) arising from any third party claim or proceeding against the ViewRay Indemnified
Party(ies) by any third party to the extent that such claim or proceeding is based on: (a) a third party assertion that the Products infringe any third party Intellectual Property Rights; or (b) a third party allegation of product
liability or personal injury arising from or relating to a manufacturing defect of the Products. The foregoing indemnification action shall not apply in the event and to the extent that such Losses arose as a result of any ViewRay Indemnified
Party’s negligence, intentional misconduct or breach of this Agreement. 
 8.3 Indemnification of Jastec. Subject to the provisions of
Section 8.4, ViewRay will defend, indemnify, and hold harmless Jastec and its Affiliates, officers, directors, employees, agents, and their successors and assigns (each, in such capacity, an “Jastec Indemnified Party”)
from and against any Losses arising from any third party claim or proceeding against the Jastec Indemnified Party(ies) by any third party to the extent that such claim or proceeding is based on: (a) any third party allegation of infringement of
third party Intellectual Property Rights, where such claim is based upon the combination, operation or use of the Products with non-Jastec technology and products in a manner not explicitly contemplated by this Agreement, if such claim of
infringement would have been avoided but for such combination, operation or use; or (b) any third party allegation of product liability or personal injury arising from or relating to the ViewRay products or services (other than due to the
failure of a Product). The foregoing indemnification action shall not apply in the event and to the extent that such Losses arose as a result of any Jastec Indemnified Party’s negligence, intentional misconduct or breach of this Agreement. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 8.4 Procedure. To receive the benefit of indemnification under Section 8.2 or Section 8.3, the
ViewRay Indemnified Party or Jastec Indemnified Party, as applicable, must: (a) promptly notify the party from whom indemnification is sought (each, an “Indemnifying Party”) of any claim or proceeding; provided, that
failure to give such notice shall not relieve Indemnifying Party of its indemnification obligations except where, and solely to the extent that, such failure actually and materially prejudices the rights of Indemnifying Party; (b) provide
reasonable cooperation to the Indemnifying Party (and its insurer), as reasonably requested, at Indemnifying Party’s cost and expense; and (c) tender to the Indemnifying Party (and its insurer) full authority to defend or settle the claim
or suit; provided that no settlement requiring any admission by the Indemnified Party or that imposes any obligation on the Indemnified Party shall be made without the Indemnified Party’s consent. Neither party has any obligation to indemnify
the other party in connection with any settlement made without the Indemnifying Party’s written consent. The Indemnified Party has the right to participate at its own expense in the claim or suit and in selecting counsel therefore. 

8.5 Insurance. Each party shall procure and maintain insurance, including product liability insurance, adequate to cover its obligations hereunder and
which are consistent with normal business practices of prudent companies similarly situated. It is understood that such insurance shall not be construed to create a limit of either party’s liability with respect to its indemnification
obligations under this Section 8. Each party shall cause the other to be listed as an additional named insured on such policy(ies) and shall provide the other with written evidence of such insurance upon request. Each party shall provide the
other with written notice at least fifteen (15) days prior to the cancellation, non-renewal or material change in such insurance or self-insurance which materially adversely affects the rights of the other party hereunder. If such party does
not obtain replacement insurance or take other measures that allow it to provide comparable coverage within such 15-day period, the other party shall have the right to terminate this Agreement effective at the end of such 15-day period without
notice or any additional waiting periods. 
 9. TERM AND TERMINATION 

9.1 Term. This Agreement shall take effect as of the Effective Date and shall remain in effect until the fifth anniversary of the Effective Date (the
“Initial Term”), unless sooner terminated in accordance with Section 9.2. This Agreement shall automatically be renewed for successive two (2) year increments (each, a “Renewal Term” and
together with the Initial Term, the “Term”) unless (i) in the case of ViewRay as the terminating party, ViewRay requests in writing, at least one-year prior to the expiration of the then-current term, and (ii) in
the case of Jastec as the terminating party, Jastec requests in writing, at least one-year prior to the expiration of the then-current term, that this Agreement not be so renewed. 

9.2 Termination. (a) Either party may terminate this Agreement upon sixty (60) days written notice if the other party commits a material
breach of this Agreement unless such breach is cured within the sixty (60) day notice period, or if such breach is not capable of being cured within sixty (60) days unless such party during such sixty (60) day period initiates actions
reasonably expected to cure the breach and thereafter diligently proceeds to cure the breach. 
 (b) ViewRay may terminate this Agreement with notice to
Jastec if a supply failure occurs and is not cured within the period specified in Section 3.10(a). 
 (c) The “disadvantaged party” (as
defined in Section 10.14) shall have the right to terminate this Agreement upon thirty (30) days’ notice if a Force Majeure condition has prevented performance by the other party for more than sixty (60) consecutive days or an
aggregate one hundred twenty (120) days in any 12-month period. 
 (d) If either party shall: (i) become bankrupt or insolvent; (ii) file for
a petition thereof; (iii) make an assignment for the benefit of creditors; or (iv) have a receiver appointed for its assets, then the other party shall be entitled to terminate this Agreement immediately upon written notice to such party.

 (e) Either party may terminate this Agreement with notice to the other party delivered within two (2) Business Days after Jastec delivers notice to
ViewRay in accordance with Section 2.1(b) that it is not able to produce the Product. 
 (f) The parties may also terminate this Agreement at any time
by mutual agreement. 
 9.3 Effect of Termination. (a) Upon termination (including expiration) of this Agreement for any reason each party shall
return to the other party or certify in writing to the other party that it has destroyed all documents (including those stored on computer systems and networks) and other tangible items it or its employees or agents have received or created
pertaining, referring or relating to the Confidential Information of the other party; provided, 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
that a party is permitted to retain one copy of such materials in its legal files to be used to verify compliance with its obligations hereunder; and provided further that this
Section 9.3(a) requires each party to (if it elects to destroy the other party’s Confidential Information to delete any Confidential Information residing on computer storage devices, but does not include deletion of archival backups copies
which are automatically generated and cannot reasonably or practically be destroyed or returned, 
 (b) Nothing herein shall be construed to release either
party of any obligation which matured prior to the effective date of any termination. Either party’s liability for any uncontested charges, payments or expenses due to the other party that accrued prior to the termination date shall not be
extinguished by termination, and such amounts (if not otherwise due on an earlier date) shall be immediately due and payable on the termination date. 
 (c)
Upon termination or expiration of this Agreement for any reason, ViewRay will have the right to continue to sell all unsold Products that are in its possession or that are subject to an open ViewRay Purchase Order as of the effective date of such
termination or expiration. In addition, upon termination or expiration of this Agreement for any reason, Jastec will continue to supply ViewRay with Products for a period of five (5) years after termination or expiration to wind-down the supply
of Products for ViewRay from Jastec, provided that if termination was effected by Jastec as a result of ViewRay’s material breach of this Agreement then ViewRay will promptly pay all sums due Jastec under this Agreement as of the date of
termination. The supply of Products by Jastec pursuant to this Section 9.3(c) shall be subject to the provisions of Sections 4-8. 
 (d) Upon any
termination or expiration of this Agreement, at ViewRay’s request, Jastec will continue to provide ViewRay with support services in accordance with Section 3.8 and Spare Parts in accordance with Section 3.9 for Products that are
installed at a ViewRay customer site or in ViewRay’s possession or that are subject to an open ViewRay Purchase Order as of the effective date of such termination or expiration or that ViewRay purchases pursuant to Section 9.3(c) for a
period of at least ten (10) years from the date such units of Product are commissioned at the ViewRay customer site. 
 9.4 Survival. Sections
1, 2.6, 3.10, 4.1, 4.2, 4.3(b), 4.4, 5-8, 9.3 (and the Sections of this Agreement referenced therein), 9.4 10.1-10.4, and 10.6-10.13 shall survive any termination or expiration of this Agreement. For the avoidance of doubt, it is understood and
agreed that termination by either party pursuant to Section 9 .2(e) shall not entitle either party to seek monetary damages from the other party and that the provisions of Section 9.3(c)-(d) shall not apply in case of a termination
pursuant to Section 9.2(e). 
 10. GENERAL PROVISIONS. 

10.1 Governing Law. This Agreement shall be governed and construed in accordance with the internal, substantive laws of New York, to the exclusion of
any choice or conflict of laws rule or provision that would result in the application of the substantive law of any other jurisdiction. The United Nations Convention on Contracts for the International Sale of Goods shall not apply to this Agreement
or the transactions contemplated by this Agreement. 
 10.2 Dispute Resolution. (a) The parties will attempt to settle any claim or controversy
arising out of this Agreement or the subject matter hereof through consultation and negotiation in good faith in a spirit of mutual cooperation. Such matters will be initially addressed by the Vice President of Manufacturing of ViewRay and the
General Manager of Sales of Jastec, who shall use reasonable efforts to attempt to resolve the dispute through good faith negotiations by telephone or in person as may be agreed. If they fail to resolve the dispute within thirty (30) days after
either party notifies the other of the dispute, then the matter will be escalated to the Chief Executive Officer of ViewRay and the Chief Executive Officer of Jastec, or their designees for resolution. They will use reasonable efforts to attempt to
resolve the dispute through good faith negotiations by telephone or in person as may be agreed. If they fail to resolve the dispute within thirty (30) days after it is referred to them and do not mutually agree to extend the time for
negotiation, then the dispute will be submitted to arbitration in accordance with the procedure set forth in Section 10.2(b). 
 (b) Except with
respect to actions by either party seeking equitable or declaratory relief, any claim or controversy arising in whole or in part under or in connection with this Agreement or the subject matter hereof that is not resolved pursuant to
Section 10.2(a) will be referred to and finally resolved by arbitration in accordance with the Rules of the International Chamber of Commerce (the “Rules”) as such Rules may be modified by this Agreement, by one
arbitrator, who will be agreed upon by the parties. If the parties are unable to agree upon a single arbitrator within thirty (30) days following the date arbitration is demanded, three arbitrators will be used, one selected by

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
each party within ten (10) days after the conclusion of the 30-day period and a third selected by the first two within 10 days thereafter. Unless the parties agree otherwise, they will be
limited in their discovery to directly relevant documents. Responses or objections to a document request will be served twenty (20) days after receipt of the request. The arbitrator(s) will resolve any discovery disputes. Either party may
commence arbitration proceedings by notice to the other party. Unless otherwise agreed by the parties, all such arbitration proceedings will be held in [San Francisco, California]. All arbitration proceedings will be conducted in the English
language and the arbitrator(s) will apply the law of New York. The arbitrator(s) will only have the authority to award actual money damages (with interest on unpaid amounts from the date due) and, except with respect to a breach or nonperformance of
any provision of this Agreement relating to Confidential Information, the arbitrator(s) will not have the authority to award indirect, incidental, consequential, exemplary, special or punitive damages, and the parties expressly waive any claimed
right to such damages. The arbitrator(s) also shall be authorized to grant any temporary, preliminary or permanent equitable remedy or relief the arbitrators deem just and equitable and within the scope of this Agreement, including an injunction or
order for specific performance. The award of the arbitrator(s) shall be the sole and exclusive remedy of the parties. The arbitration will be of each party’s individual claims only, and no claim of any other party will be subject to arbitration
in such proceeding. The parties will share the costs and expenses of the arbitration, but not the costs and expenses of the parties, equally. If a party fails to proceed with arbitration, unsuccessfully challenges the arbitration award, or fails to
comply with the arbitration award, the other party is entitled to costs, including reasonable attorneys’ fees, for having to compel arbitration or defend or enforce the award. Except as otherwise required by law, the parties and the
arbitrator(s) will maintain as confidential all information or documents obtained during the arbitration process, including the resolution of the dispute. Judgment on the award granted in any arbitration hereunder may be entered in any court having
jurisdiction over the award or any of the parties or any of their respective assets. The parties knowingly and voluntarily waive their rights to have their dispute tried and adjudicated by a judge and jury except as expressly provided herein. 

(c) Nothing in this Section 10.2 will prevent a party from resorting to judicial proceedings if: (i) interim relief from a court is necessary to
prevent serious and irreparable injury to such party; or (ii) litigation is required to be filed prior to the running of the applicable statute of limitations. The use of any alternative dispute resolution procedure will not be construed under
the doctrine of latches, waiver or estoppel to affect adversely the rights of either party. 
 10.3 Amendment and Waiver. No provision of or right
under this Agreement shall be deemed to have been waived by any act or acquiescence on the part of either party, its agents or employees, but only by an instrument in writing signed by an authorized officer of each party. No waiver by either party
of any breach of this Agreement by the other party shall be effective as to any other breach, whether of the same or any other term or condition and whether occurring before or after the date of such waiver. 

10.4 Independent Contractors. Each party represents that it is acting on its own behalf as an independent contractor and is not acting as an agent for
or on behalf of any third party. This Agreement and the relations hereby established by and between ViewRay and Jastec do not constitute a partnership, joint venture, franchise, agency or contract of employment. Neither party is granted, and neither
party shall exercise, the right or authority to assume or create any obligation or responsibility on behalf of or in the name of the other party or its Affiliates. Each party shall be solely responsible for compensating all its personnel and for
payment of all related FICA, workers’ compensation, unemployment and withholding taxes. Neither party shall provide the other party’s personnel with any benefits, including but not limited to compensation for insurance premiums, paid sick
leave or retirement benefits. 
 10.5 Assignment. Neither party may assign this Agreement or any of its rights and obligations under this Agreement
without the prior written consent of the other party; provided, that ViewRay may assign this Agreement without the consent of Jastec to an Affiliate or in connection with any merger, acquisition, or sale a majority of its’ voting stock or a
sale of substantially all of its’ assets. Any purported assignment in violation of this Section 10.5 shall be null and void. 
 10.6 Successors
and Assigns. This Agreement shall bind and inure to the benefit of the parties hereto and their respective successors and permitted assigns. 
 10.7
Notices. Unless otherwise provided herein, any notice, report, payment or document to be given by one party to the other shall be in writing and shall be deemed given when delivered personally or mailed by certified or registered mail, postage
prepaid (such mailed notice to be effective on the date which is three (3) Business Days after the date of mailing), or sent by nationally recognized overnight courier (such notice sent by courier to be effective one (1) Business Day after
it is deposited with such courier), or sent by telefax (such notice sent by telefax 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
to be effective when sent, if confirmed by certified or registered mail or overnight courier as aforesaid) to the address set forth on the signature page to this Agreement or to such other place
as any party may designate as to itself by written notice to the other party. 
 10.8 Severability. In the event any provision of this Agreement
shall for any reason be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other term or provision hereof. The parties agree that they will negotiate in good faith or
will permit a court to replace any provision hereof so held invalid, illegal or unenforceable with a valid provision which is as similar as possible in substance to the invalid, illegal or unenforceable provision. 

10.9 Captions. Captions of the Sections and paragraphs of this Agreement are for reference purposes only and do not constitute terms or conditions of
this Agreement and shall not limit or affect the meaning or construction of the terms and conditions hereof. 
 10.10 Word Meanings. Words such as
herein, hereinafter, hereof and hereunder refer to this Agreement as a whole and not merely to a section or paragraph in which such words appear, unless the context otherwise requires. The singular shall include the plural, and each masculine,
feminine and neuter reference shall include and refer also to the others, unless the context otherwise requires. 
 10.11 Entire Agreement. The terms
and provisions contained in this Agreement (including the Attachments) constitute the entire understanding of the parties with respect to the transactions and matters contemplated hereby and supersede all previous communications, representations,
agreements and understandings relating to the subject matter hereof. No representations, inducements, promises or agreements, whether oral or otherwise, between the parties not contained in this Agreement shall be of any force or effect. No
agreement or understanding extending this Agreement or varying its terms (including any inconsistent terms in any purchase order, acknowledgment or similar form) shall be binding upon either party unless it is in a writing specifically referring to
this Agreement and signed by a duly authorized representative of the applicable party. 
 10.12 Rules of Construction. The parties agree that they
have participated equally in the formation of this Agreement and that the language and terms of this Agreement shall not be construed against either party by reason of the extent to which such party or its professional advisors participated in the
preparation of this Agreement. 
 10.13 Counterparts. This Agreement may be executed in multiple counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. Facsimile signatures shall be accepted as original signatures, orders may be transmitted electronically and any document created pursuant to this Agreement may be
maintained in an electronic document storage and retrieval system, a copy of which shall be considered an original. 
 10.14 Force Majeure. Except as
otherwise provided in this Agreement, in the event that a delay or failure of a party to comply with any obligation created by this Agreement is caused by acts of God, wars (declared or undeclared and including the continuance, expansion or new
outbreak of any war or conflict now in existence), revolution, civil commotion, acts of public enemy, labor strikes (other than employees of the affected party), terrorism, embargo or acts of government in its sovereign capacity, or other cause
outside the reasonable control of the affected party and without its fault or negligence (collectively, “Force Majeure”), the “affected party” will, after giving prompt notice to the “disadvantaged party,”
be excused from such performance on a day-to-day basis during the continuance of such prevention, restriction, or interference (and the disadvantaged party will likewise be excused from performance of its obligations on a day-to-day basis during the
same period), provided, however, that the affected party will use its best efforts to avoid or remove the causes of nonperformance and both parties will proceed immediately with the performance of their obligations under this Agreement whenever the
causes are removed or cease. If Force Majeure conditions continue for more than sixty (60) consecutive days or an aggregate one hundred twenty (120) days in any 12-month period, then the disadvantaged party may terminate this Agreement in
accordance with Section 9.2(c). 
 10.15 Other Products. During the Term, ViewRay may seek additional development services from Jastec with respect
to new or modified versions of the Product embodying improvements and enhancements. If the parties agree to work together to develop such new or modified versions of the Product then they shall do so pursuant to the terms of this Agreement but
subject to their entering into a separate Attachment 1 describing the “Program” for the development of such new or modified version(s) of the Product and a separate Attachment 2 covering the
pricing for such work for such new or modified version of the Product; such Attachment 1 and Attachment 2 to contain mutually acceptable terms. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 IN WITNESS WHEREOF the parties have caused this Agreement to be executed on their behalf by their duly authorized
representatives intending it to take effect as an instrument under seal as of the Effective Date. 
  

									
	JAPAN SUPERCONDUCTOR TECHNOLOGY, INC.	 		 	VIEWRAY INCORPORATED
					
	By:	 	 /s/ Yoshiro Nishimoto
	 		 	By:	 	 /s/ Chris Raanes

		 	Yoshiro Nishimoto, Chief Executive Officer	 		 		 	Chris Raanes, Chief Executive Officer
		 		 	
	Notice Address:	 		 	Notice Address:
	 Japan Superconductor Technology, Inc.

c/o General Technical Laboratory, Kobe Steel, Ltd.
 Takatsukadai
1-5-5, Nishi-ku
 Kobe, Hyogo
 Japan 651-2271
	 		 	  
 ViewRay Incorporated

2 Thermo Fisher Way
 Oakwood Village, OH 44146

United States of America

			
		
	 Attachment 1
	  	Product Specifications; Program
	 Attachment 2
	  	Pricing
	 Attachment 3
	  	ATP [to be supplied when approved by the parties]

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Attachment 1  

Product Specifications; Program 

Specifications: see attached TECHNICAL SPECIFICATION FOR [***] 

Program: 
 ViewRay requires the development of a Product
as specified in the Specifications. The manufacture of the Product is divided into [***] phases as follows: 
  

							
	 Phase
	  	 Scope and Activities
	  	 Deliverable
	  	 Schedule

	[***]	  	[***]	  	[***]	  	[***]

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Attachment 2  

Pricing 
 1. Product Pricing 

 

			
	Product Unit No.	  	Price (USD) per Unit of Product
	 [***]
	  	[***]

 Products shall be invoiced in installments as follows: 

(a) For Product units Nos. [***]: 
 (i) up to [***] percent
([***]%) of the purchase price for the Product shall be invoiced by Jastec on the date the Purchase Order for such Product is accepted by Jastec and shall be due within sixty (60) days of receipt of invoice; provided that in the event and to the
extent that third party component suppliers for the Product require a lesser payment percentage at the time Jastec submits a purchase order for such components then the [***]% figure shall be subject to a corresponding reduction so that ViewRay is
providing Jastec with the funds necessary to cover the smaller deposit required by the third party component supplier; 
 (ii) [***] percent ([***]%) of the
purchase price for the Product shall be invoiced by Jastec on the date that Jastec notifies ViewRay that it has completed winding of the Product and shall be due within sixty (60) days of receipt of invoice; and 

(iii) the balance of the purchase price for the Product shall be invoiced on the date the Product passes the factory acceptance test in accordance with
Section 3.7(a) and ViewRay has completed document review for such Product and confirmed that it conforms to the Product Specifications concerning such documentation and shall be due within sixty (60) days of receipt of invoice. ViewRay shall
complete such document review within one week following the date the Product passes the factory acceptance test and such documentation has been made available to ViewRay. 

(b) For Product units Nos. [***]: (i) [***] percent ([***]%) of the purchase price for the Product shall be invoiced by Jastec on the date that
Jastec notifies ViewRay that it has completed winding of the Product and shall be due within sixty (60) days of receipt of invoice; 
 (ii) [***] percent
([***]%) of the purchase price for the Product shall be invoiced on the date the Product passes the factory acceptance test in accordance with Section 3.7(a) and ViewRay has completed document review for such Product and confirmed that it
conforms to the Product Specifications concerning such documentation and shall be due within sixty (60) days of receipt of invoice. ViewRay shall complete such document review within one week following the date the Product passes the factory
acceptance test and such documentation has been made available to ViewRay; and 
 (iii) [***] percent ([***]%) of the purchase price for the Product shall
be invoiced by Jastec on the date of shipment of the Product to ViewRay or its designee and shall be due within sixty (60) days of receipt of invoice. 

(c) For Product units Nos. 11 and subsequent: (i) [***] percent ([***]%) of the purchase price for the Product shall be invoiced on the date the
Product passes the factory acceptance test in accordance with Section 3.7(a) and ViewRay has completed document review for such Product and confirmed that it conforms to the Product Specifications concerning such documentation and shall be due
within sixty (60) days of receipt of invoice. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 ViewRay shall complete such document review within one week following the date the Product passes the factory
acceptance test and such documentation has been made available to ViewRay; and 
 (ii) [***] percent ([***]%) of the purchase price for the Product shall be
invoiced by Jastec on the date of shipment of the Product to ViewRay or its designee and shall be due within sixty (60) days of receipt of invoice. 
  

	2.	Spare Parts Pricing 

 The pricing applicable to Spare Parts shall be established by mutual agreement of
the parties within 8 months following the Effective Date. 
  

	3.	Installation Charges 

 A separate installation charge shall apply for Jastec installation support
services provided to ViewRay pursuant to Section 3.8(a) of the Agreement. The charge shall be established by mutual agreement of the parties within 8 months following the Effective Date. Installation charges shall be invoiced by Jastec after
ViewRay customer sign-off of the site visit report and shall be due within sixty (60) days of receipt of invoice. 
  

	4.	Support Services Charges 

 A separate support services charge shall apply for Jastec Product support
services provided to ViewRay pursuant to Section 3.8(b) of the Agreement. The charge shall be established by mutual agreement of the parties within 8 months following the Effective Date. This charge shall not apply to support services rendered
during the product warranty period and will only apply to services provided after the warranty period has expired. Support services charges shall be invoiced by Jastec on a monthly basis and shall be due within sixty (60) days of receipt of invoice.

  

	5.	Documentation of Price Adjustments 

 The parties shall document any price adjustments made
pursuant to Section 3.5(e) of the Agreement using a short form amendment to this Attachment 2 that shall update such pricing and be signed by each party in accordance with Section 10.3 of the Agreement. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.EX-10.21(a)

 Exhibit 10.21(a) 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
 Development and Supply Agreement 

between 
 Viewray, Inc.,

 with its registered seat in Beachwood, OH, USA 

- hereinafter referred to as “VIEWRAY” - 

and 
 SIEMENS
Aktiengesellschaft, Healthcare Sector  
 with its registered seat in Berlin and Munich, 

Federal Republic of Germany 
 -
hereinafter referred to as “SIEMENS” – 
 - VIEWRAY and SIEMENS hereinafter referred to individually 

as “PARTY” or collectively as “PARTIES” - 

 Preamble 

VIEWRAY has experience and know-how about the combination of Magnetic Resonance Imaging (“MRI”) and Gamma Ray Radiotherapy (“RT”) to
provide real-time beam-on imaging and targeting of tumors. In addition to that, a combination of MRI systems with RT devices promises the acquiring healthcare facility appreciable cost savings by reducing staff time requirements and
streamlining the workflow process via task simplification. In order to achieve a fast time to market for MR guided Gamma Ray Radiotherapy (“MRgRT”), VIEWRAY has an interest to find an experienced partner in the field of MRI. 

SIEMENS has over 25 years of experience, know-how and comprehensive intellectual property in MRI systems, solutions and services. Today, SIEMENS is the
market leader in the MRI industry due to its long-standing technology and innovation leadership. To further expand this leadership position, SIEMENS is interested to enter the field [***]. 

The PARTIES intend to combine their know-how and experience for the purpose of forming a long-term business relationship for the supply of Magnetic Resonance
Imaging (“MRI”) subsystems (“COMPONENTS”) for MRgRT systems to provide real-time beam-on imaging and targeting of tumors. 
 The
business relationship shall be divided into the following three phases: 
 PHASE 1: Validation of the real-time MR imaging
requirements of a future the MRgRT system. 
 PHASE 2: Validation of the integration and interaction on of the RT system
with the MRI system. 
 PHASE 3: Supply of COMPONENTS by SIEMENS for the VIEWRAY MRgRT system in serial production in accordance
with the OEM-Sales Agreement as per Appendix 2. 
 The terms and conditions of the three PHASES in this business relationship are described in
the following articles. 
 Article 1—Definitions 
  

	1.1	The term “INFORMATION” means any methods, processes, know-how, proprietary information, trade secrets, technology, designs, digital codes, software, inventions, innovations and improvements relating to MRgRT
or MRI whether or not protected or protectable by IPR, owned or controlled by either PARTY prior to the date of this Agreement, or which becomes owned or controlled by either PARTY during the term of this Agreement outside of the PROJECT.

  

	1.2	The term “IPR” means all patents, patent applications and copyrights, as well as other forms of statutory protection rights. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	1.3	The term “PROJECT” means the research and development program to be conducted by the PARTIES, as more fully described in Article 2, 3 and 4 hereinafter. 

 

	1.4	The term “DOCUMENTATION” shall mean written INFORMATION. 

  

	1.5	The term “BACKGROUND PATENTS” shall mean copyrights, utility models, patent applications and patents covering INFORMATION. 

 

	1.6	The term “WORK” means collectively any and all work, services, contributions, investigations etc. performed and rendered during and for the purpose of the PROJECT. The WORK is detailed in Article 2, 3 and
4 hereinafter. 

  

	1.7	The term “RESULTS” means any and all methods, processes, know-how, proprietary information, trade secrets, technology, designs, digital codes, software, inventions, innovations and improvements made by either
PARTY in connection with the PROJECT, whether or not protected or protectable by IPR. 

  

	1.8	The term “FIELD” means the development, production, use, marketing, sale and support of a system with MR guided Gamma Ray Radiotherapy (MRgRT) functionality 

 

	1.9	The term “AFFILIATES” shall mean companies of which SIEMENS or VIEWRAY, as applicable, owns or controls, directly or indirectly at least 50 % of the stock or voting rights. 

 

	1.10	The term “CHANGE OF CONTROL” means with respect to VIEWRAY, in an event or series of related events: (a) a sale of all or substantially all of VIEWRAY’s assets, voting stock or securities or business
relating to this Agreement; (b) a merger, reorganization or consolidation involving VIEWRAY in which the stockholders of VIEWRAY immediately prior to such transaction cease to own collectively a majority of the voting equity securities of the
successor entity; or (c) a Person or group of Persons acting in concert acquire fifty percent (50%) or more of the voting equity securities of VIEWRAY. For purposes of clarity, the term “CHANGE OF CONTROL” is not intended to
include (i) an underwritten public offering of VIEWRAY’s common stock pursuant to a Registration Statement on Form S-1 under the Securities Act of 1933, as amended, or (ii) any sale of shares of capital stock of VIEWRAY, in a single
transaction or series of related transactions principally for bona fide equity financing purposes in which VIEWRAY issues new securities to venture capital investors primarily for cash or the cancellation or conversion of indebtedness of VIEWRAY or
a combination thereof for the purpose of financing the operations and business of VIEWRAY. 

 Article 2 – PHASE 1 of Business
Relationship 
  

	2.1	For the purpose of the validation of the MR imaging requirements for a future MRgRT system, SIEMENS will convert a mobile [***] MRI system to work at 0.35 Tesla. The MRI system specifications are as described in the
[***] data sheet attached as Appendix 0. The MRI system will include a [***] and [***]. The system will not include [***] and [***]. Any changes to the specifications of the mobile [***] MRI system due to the operation at 0.35T that are
not documented in Appendix 0 need to be mutually agreed on by the PARTIES in good faith. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	2.2	After conversion, the MRI system will be delivered to VIEWRAY’s premises. The MRI system will be locally installed, including MRI system start-up and tune-up (together with VIEWRAY). 

 

	2.3	SIEMENS will provide on-site support for the MRI system hardware by a SIEMENS System Engineer. 

  

	2.4	SIEMENS will provide on-site support for MRI sequence and application optimization together with VIEWRAY in order to achieve real-time requirements by a SIEMENS Application Specialist. 

 

	2.5	The associated costs for the supply of the mobile MRI system and the engineering support during PHASE 1 will be described in Appendix 1. For the rest each PARTY shall bear the costs incurred by such
PARTY for its efforts under or in connection with the work performed under PHASE 1. 

  

	2.6	PHASE 1 will be completed after successful demonstration of MRI imaging requirements for a future MRgRT system. The completion of PHASE 1 will be documented in a joint review meeting by both PARTIES, based
upon a review if the validation tests fulfilled all the specifications as described in Appendix 0 as well as the mutually agreed changes to the specification of the mobile [***] MRI system due to the to the operation at 0.35T. After
acceptance of the completion of PHASE 1, PHASE 2 of the Agreement shall commence. 

  

	2.7	If the validation test results of the development work during PHASE 1 show that specifications as described in Appendix 0 as well as the mutually agreed changes to the specifications of the mobile [***]
MRI system due to the to the operation at 0.35T adopted in accordance with Article 2.1 are not fulfilled or partially not fulfilled, both PARTIES will use Commercially Reasonable Efforts to agree on a remediation plan as soon as reasonably
possible, but not exceeding 45 days following such events and use Commercially Reasonable Efforts to implement such plan to cure such deficiencies. If there is no agreement on such a remediation plan within that time period, then either PARTY
shall be entitled to terminate this Agreement. If the parties are not successful in curing deficiencies pursuant to the plan adopted pursuant to this Article 2.7 then they shall repeat the above process once more and if they are unable to cure
the deficiencies on such second attempt then either PARTY may terminate this Agreement. 

  

	2.8	VIEWRAY may, at any time prior to the commencement of PHASE 2, purchase COMPONENTS from SIEMENS under terms equivalent to those specified in Annex 2 of the SUPPLY AGREEMENT attached as Appendix 2
hereto. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Article 3 – PHASE 2 of Business Relationship 

 

	3.1	For the purpose of validating the integration and interaction of the RT system with the MRI system, VIEWRAY will test their RT system components together with the SIEMENS MRI system to identify any potential
artifacts caused by the integration. If VIEWRAY identifies such artifacts and proposes any changes to the specifications of the mobile [***] MRI system due to the combined use with the RT system components, such proposed changes need to be mutually
agreed on by the PARTIES at the beginning of PHASE 2; such agreement not to be unreasonably withheld. For purposes of establishing such specifications, VIEWRAY shall provide SIEMENS with draft specifications for PHASE 2 not later than
15 Business Days following the PHASE 1 completion date and SIEMENS shall notify VIEWRAY within 10 Business Days thereafter whether it accepts such specifications or proposes changes thereto. The PARTIES shall agree on such
specifications within 30 Business Days following the PHASE 1 completion date or shall meet to mutually resolve such specifications and shall resolve such specifications to their mutual satisfaction not later than the beginning of
PHASE 2. Thereafter, any changes to the specifications of the MRgRT System, including the modified [***] MRI system portion of such MRgRT System, need to be mutually agreed on by the PARTIES. 

 

	3.2	VIEWRAY may at any time purchase COMPONENTS from SIEMENS in order to facilitate validation work in PHASE 2. 

  

	3.3	SIEMENS will continue to provide on-site support for the MRI system hardware by a SIEMENS System Engineer in PHASE 2. Necessary modifications to the MRI system as agreed by the PARTIES pursuant to Section 3.1
will be done by the SIEMENS System Engineer on site. 

  

	3.4	SIEMENS will continue to provide on-site support for MRI sequence and application optimization together with VIEWRAY in order to achieve real-time requirements by a SIEMENS Application Specialist, if necessary in
PHASE 2. 

  

	3.5	The associated costs for the supply of the mobile MRI system and the engineering support during PHASE 2 will be described in Appendix 1. For the rest each PARTY shall bear the costs incurred by such
PARTY for its efforts under or in connection with the work performed under PHASE 2. 

  

	3.6	PHASE 2 will be completed after successful demonstration of the integration of the RT system with the MRI system. The completion of PHASE 2 will be documented in a joint review meeting by both PARTIES, based
upon a review if the validation tests fulfilled all the specifications as described in Article 2.1 as well as the mutually agreed changes to the specifications of the mobile [***] MRI system due to the combined use with the RT system
components. 

  

	3.7	 If the validation test results of the development work during PHASE 2 show that specifications as described
in Article 3.1 as well as the mutually agreed changes to the specifications of the mobile [***] MRI system due to the combined use with the RT system components are not fulfilled or partially not fulfilled, both PARTIES will use
Commercially Reasonable Efforts to agree upon a remediation plan as soon as reasonably possible, but not exceeding 45 days following such events and use Commercially Reasonable Efforts to implement such plan to cure such deficiencies. If there
is no agreement on such a remediation plan within that time period, then either PARTY shall 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	 	
be entitled to terminate this Agreement. If the parties are not successful in curing deficiencies pursuant to the plan adopted pursuant to this Article 3.7 then they shall repeat the above
process once more and if they are unable to cure the deficiencies on such second attempt then either PARTY may terminate this Agreement. 

  

	3.8	At any point after completion of PHASE 1, but not later than at completion of PHASE 2, VIEWRAY may terminate the rental agreement of the mobile MRI system. After termination of the rental agreement, the MRI
system will be converted back to a standard mobile [***] MRI system. 

 Article 4 – PHASE 3 of Business Relationship 

 

	4.1	After successful completion of PHASE 2, SIEMENS shall supply COMPONENTS to VIEWRAY in accordance with the stipulations of the Supply Agreement attached as Appendix 2 hereto (the “SUPPLY
AGREEMENT”) and in case of any inconsistency between any provision of Articles 1 to 13 and the provisions of the SUPPLY AGREEMENT, the SUPPLY AGREEMENT shall prevail. The date of the documented review meeting (see Article 3.6) shall
be treated as the effective date for the SUPPLY AGREEMENT (“EFFECTIVE DATE II”), which shall take effect automatically and without signature upon the PARTIES determination that PHASE 2 has been successfully completed in
accordance with Article 3.6. 

  

	4.2	SIEMENS will support the product development work for the MRgRT system by providing a SIEMENS System Engineer, to be located at VIEWRAY’s premises during the initial term of the SUPPLY AGREEMENT up to a maximum of
three years. A possible continuation of such support for modifications of the MRgRT system needs to be mutually agreed after that time period (i.e., after the initial 3-year term of the SUPPLY AGREEMENT). The costs for the SIEMENS System Engineer,
including relocation expenses, shall be reimbursed by VIEWRAY and are based on the rates as described in Appendix 1. 

  

	4.3	VIEWRAY will use standard COMPONENTS from SIEMENS wherever possible. SIEMENS will modify COMPONENTS to allow full function of the integrated MRgRT system if necessary or useful, technically feasible and commercially
reasonable. Changes in the measurement and control system of the COMPONENTS are exempt from this Article 4.3. Change requests made during PHASE 3, shall be made pursuant to Section 8.3 of the SUPPLY AGREEMENT. 

 

	4.4	SIEMENS will provide VIEWRAY access to all available regulatory documentation to assist in FDA submissions by VIEWRAY. SIEMENS will notify VIEWRAY without undue delay in case SIEMENS COMPONENTS are involved in any
product recall actions that might affect the FDA approval of the VIEWRAY MRgRT system. 

  

	4.5	SIEMENS will provide VIEWRAY with all necessary service documentation available at SIEMENS, such documentation to be provided pursuant to the Quality Agreement contemplated by the SUPPLY AGREEMENT. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	4.6	Service topics, including, but not limited to 

  

	 	•	 	Service contracts 

  

	 	•	 	Spare parts supply and logistics 

  

	 	•	 	First, second and third level service support 

  

	 	•	 	Software and computer hardware upgrades for the installed base 

 are regulated in the SUPPLY
AGREEMENT Section 7. 
 Article 5—Exclusivity of Business Relationship 

For the duration of PHASE 1 and PHASE 2, the PARTIES will cooperate in regard to the PROJECT and within the FIELD on an exclusive basis. 

Article 6—Secrecy 
  

	6.1	Each PARTY agrees that all INFORMATION and RESULTS which it receives from the other PARTY and which are designated as confidential by such PARTY will be deemed to be confidential and will be maintained by the receiving
PARTY in confidence, provided, however, that such PARTY may disclose such information to its officers, and those of its employees and others under its control for the purposes of this Agreement, all of whom will be advised of this Agreement and such
PARTY’s obligations there under. 

  

	6.2	Such PARTY additionally agrees to take all reasonable precautions to safeguard the confidential nature of the foregoing information, provided, however, that such PARTY’s normal procedures for protecting its own
confidential information shall be deemed reasonable precautions, and provided that if such precautions are taken, such PARTY will not be liable for any disclosure which is inadvertent or unauthorized or is required by any judicial order or decree or
by any governmental law or regulation. Neither shall such PARTY be liable for disclosure and/or any use of such information insofar as such information 

  

	 	•	 	is in, or becomes part of, the public domain other than through a breach of this Agreement by such PARTY; 

  

	 	•	 	is already known to such PARTY at or before the time it receives the same from the other PARTY or is disclosed to such PARTY by a third PARTY as a matter of right; 

 

	 	•	 	is independently developed by such PARTY without the benefit of such information received from the other PARTY; 

  

	 	•	 	is disclosed and/or used by such PARTY with the prior written consent of the other PARTY. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Notwithstanding the above, each PARTY has the right to disclose the other PARTY’s INFORMATION and RESULTS
which it received under this Agreement to its licensees insofar as it has the right to sublicense same as set forth in this Agreement, provided, such PARTY requires such licensee to undertake in writing secrecy obligations which are at least as
stringent as the ones set forth in this Article 6; 
  

	6.3	The obligations of Article 6 shall survive five years after termination of this Agreement. 

 Article
7—Warranties and Limitation of Liabilities 
  

	7.1	Provided it complies with the provisions of Article 1, 2 and 3 above, no PARTY shall be liable towards the other PARTY in the case that the WORK cannot be successfully completed. 

 

	7.2	The sole obligation of each PARTY with respect to its INFORMATION and RESULTS shall be to forward same to the other PARTY as provided in this Agreement and, to correct errors that might have occurred in this INFORMATION
and RESULTS without undue delay after such errors become known to the PARTY which forwarded the relevant INFORMATION or RESULTS. 

The warranties set forth in this Article 7.2 apply to all INFORMATION and RESULTS licensed or knowingly disclosed hereunder and are in
lieu of all warranties expressed or implied including without limitation the warranties that INFORMATION and RESULTS can be used without infringing statutory and other rights of third PARTIES. 

 

	7.3	Any liability of a PARTY with respect to death or injury to any person is subject to and governed by the provisions of the applicable law. Neither PARTY is, however, obliged to compensate for death or personal injury or
loss of or damage to property of the other PARTY to the extent such death, injury, loss or damage is covered by insurance(s) of the affected PARTY and such affected PARTY shall not be entitled to recover same from the first PARTY. 

 

	7.4	Neither PARTY shall be liable for any indirect or consequential damages of the other PARTY, including loss of profit or interest, under any legal cause whatsoever and on account of whatsoever reason, except where such
liability is mandatory by applicable law. 

  

	7.5	Nothing in this Agreement shall obligate either PARTY to apply for, take out, maintain or acquire any statutory protection, in any country. 

 

	7.6	All rights granted in INFORMATION, RESULTS and under BACKGROUND PATENTS are granted insofar only as the PARTY granting same has the right to grant without payment to third PARTIES. 

 

	7.7	The provisions of Sections 7.1 through 7.6 shall survive any termination of this Agreement. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Article 8—Intellectual Properties 

 

	8.1	Inventions—including, but not being limited to, inventions eligible for statutory protection (patent applications, patents, etc.)—made during the term and under the cooperation of this Agreement
(“INVENTIONS”) by employees of one PARTY shall become neither the property of the other PARTY nor the common property of both PARTES, and the one PARTY, therefore and insofar as it otherwise has the right to do so, shall be free to use
such INVENTIONS as it sees fit and to file for statutory protection and to use, maintain and permit to lapse such application for statutory protection and any statutory rights issued thereon. 

 

	8.2	INVENTIONS made by employees of both PARTIES (“JOINT INVENTIONS”) shall, at the time they are made, become the joint property of both PARTIES. 

 

	8.2.1	JOINT INVENTIONS, including any and all statutory protection issuing thereon (as per Section 8.2.2, below, or otherwise), if any, may be used by each PARTY as such PARTY sees fit. Each PARTY, therefore, for example
and without limitation, has the transferable right to grant non-exclusive, further transferable licenses under such JOINT INVENTIONS. 

  

	8.2.2	For JOINT INVENTIONS which are eligible for statutory protection the PARTIES will agree upon the details for filing for such protection. 

In case only one (1) PARTY is interested in filing for statutory protection for JOINT INVENTIONS, then the other PARTY shall execute and
forward to the one PARTY all documents requested by the one PARTY and reasonably believed to be necessary and/or desirable for such procedure. Statutory rights filed for JOINT INVENTIONS by one PARTY at its own expense shall, from the date of
filing, become the sole property of that one PARTY, and, therefore, for example and without limitation, can be used, maintained and permitted to lapse by this PARTY as it sees fit. The other PARTY’S rights to use such statutory rights are as
laid down in Section 8.2.1, above. 
  

	8.2.3	Each PARTY ensures that it will be in a position to immediately acquire the share of inventions of its employees insofar as JOINT INVENTIONS are concerned. 

 

	8.2.4	Neither PARTY is obligated to take action against third PARTIES infringing upon statutory rights filed or issued for JOINT INVENTIONS or to defend such rights against third PARTIES. 

 

	8.3	(a) Under its INFORMATION, BACKGROUND PATENTS and RESULTS each PARTY hereby grants to the other PARTY the non-exclusive, non-transferable, royalty free right and license, including the right to sublicense to
SIEMENS AFFILIATES, to use same during the term of this Agreement solely for the purpose of carrying out the WORK assigned to such PARTY. This right includes the right to have such INFORMATION, BACKGROUND PATENTS and RESULTS used by a subcontractor.

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (b) Under its INFORMATION, BACKGROUND PATENTS and RESULTS each PARTY hereby grants to the other
PARTY the non-exclusive, non-transferable, royalty free right and license, to use same within the FIELD for the manufacture, use and sale of the VIEWRAY MRgRT system and its parts and modifications and enhancement thereof and to grant sublicenses as
part of a grant of a license under its own technology. 
  

	8.4	INFORMATION and RESULTS, which one PARTY receives from the other under this Agreement may be used by the receiving PARTY outside the FIELD as such PARTY seems fit, provided, however, that no rights are granted in this
Article 8.4 under any present or future statutory rights, including without limitation BACKGROUND PATENTS, with the exception of JOINT INVENTIONS as set forth in Article 8.2. 

 

	8.5	The stipulations of Articles 8.1 through 8.4 shall survive any termination of this Agreement. 

 Article
9—CHANGE OF CONTROL 
  

	9.1	If VIEWRAY obligates itself with respect to a CHANGE OF CONTROL with a third party that is an “INDIRECT COMPETITOR” of SIEMENS, the PARTIES will discuss in good faith within thirty (30) days after such
CHANGE OF CONTROL is publicly announced, how such CHANGE OF CONTROL would impact the relationship contemplated by this Agreement, including whether VIEWRAY or such INDIRECT COMPETITOR will terminate this Agreement after the closing of such CHANGE OF
CONTROL transaction. SIEMENS shall be entitled to terminate this Agreement within a period of thirty (30) days following the receipt of such a notification and discussion if it is not reasonably assured that such CHANGE OF CONTROL will not
adversely affect the prospects for commercial success of the transactions contemplated by this Agreement. With respect to a CHANGE OF CONTROL involving a “DIRECT COMPETITOR”, SIEMENS shall be entitled to terminate this Agreement within a
period of thirty (30) days following the receipt of such a notification at its own discretion. For purposes of this Agreement, “DIRECT COMPETITOR” means an entity that has an MRI product line. As of the Effective Date I, DIRECT
COMPETITORS may include each of GE Healthcare, Hitachi Medical Systems Corporation, Toshiba Medical Systems Corporation and Philips Healthcare or their respective affiliates. For purposes of this Agreement, “INDIRECT COMPETITOR” means an
entity that is not a DIRECT COMPETITOR but which has a product line that competes with another product line of SIEMENS. 

  

	9.2	In case of termination of this Agreement by VIEWRAY following a CHANGE OF CONTROL involving a DIRECT COMPETITOR or INDIRECT COMPETITOR prior to the commencement of PHASE 3, VIEWRAY shall reimburse SIEMENS for lost
revenue pursuant to this Agreement. This includes the complete payment of all outstanding purchase orders of COMPONENTS and equipment rental as well as engineering and application support services provided pursuant to this Agreement from the date
such CHANGE OF CONTROL transaction is publicly announced. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	9.3	In case of termination of this Agreement by SIEMENS in accordance with Article 9.1, SIEMENS will not have a right of any compensation for lost revenue pursuant to Article 9.2. 

Article 10—Term and Termination 
  

	10.1	This Agreement shall become effective on the date it is signed by both PARTIES (EFFECTIVE DATE I). This Agreement may be terminated at any time within PHASE 1 and PHASE 2 by the one PARTY by giving of not less
than four weeks’ prior written notice to the other PARTY 

 — if the other PARTY hereto is declared bankrupt or
otherwise cannot fulfill its financial obligations; or 
 — if the other PARTY hereto substantially defaults in the performance of this
Agreement and does not remedy the default within four (4) weeks after receipt of a relevant request of the one PARTY; or 
 — if
the other PARTY extends its activities to cover the development and/or manufacture of COMPONENTS or parts within the FIELD and should such extension not be governed by the cooperation of the PARTIES hereunder. 

 

	10.2	These rules refer solely to a termination during Phase 1 and Phase 2. Termination of the SUPPLY AGREEMENT is governed in Section 13 therein. 

Article 11—Arbitration 
  

	11.1	Any differences or disputes arising from this Agreement or from agreements regarding its performance shall be settled by an amicable effort on the part of both PARTIES to the Agreement. An attempt to arrive at a
settlement shall be deemed to have failed as soon as one of the PARTIES to the Agreement so notifies the other PARTY in writing. 

  

	11.2	If an attempt at settlement has failed, the disputes shall be finally settled under the Rules of Conciliation and Arbitration of the International Chamber of Commerce in Paris (Rules) by three arbitrators appointed in
accordance with the Rules. 

  

	11.3	The place of arbitration shall be Zurich, Switzerland. The procedural law of this place shall apply where the Rules are silent. 

  

	11.4	The arbitral award shall be substantiated in writing. The arbitral tribunal shall decide on the matter of costs of the arbitration. 

  

	11.5	Any claim, controversy or dispute between the PARTIES arising in whole or in part under or in connection with this Agreement or the subject matter hereof will, before such submission to arbitration, first be escalated
to the MRI Business Unit Chief Executive Officer of SIEMENS and the Chief Executive Officer of VIEWRAY for resolution. They will use reasonable efforts to attempt to resolve the dispute through good faith negotiations by telephone or in person as
may be agreed and if they fail to resolve the dispute within thirty (30) days after either party notifies the other of the dispute, and do not mutually agree to extend the time for negotiation, then the dispute will be submitted to arbitration
in accordance with the procedure set forth in Articles 11.1-11.4. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Article 12—Substantive Law 
  

	12.1	All disputes shall be settled in accordance with the provisions of this Agreement and all other agreements regarding its performance, otherwise in accordance with the substantive law in force in Switzerland, without
reference to other laws. 

  

	12.2	Nothing contained herein shall be construed and the PARTIES hereby waive any and all rights they may have to claim or assert, that SIEMENS is subject to the jurisdiction of the courts of the USA. 

Article 13—Miscellaneous 
  

	13.1	This Agreement may not be released, discharged, abandoned, changed or modified in any manner, except by an instrument in writing signed on behalf of each of the PARTIES hereto by their duly authorized representatives.

  

	13.2	The failure of any PARTY hereto to enforce at any time any of the provisions of this Agreement shall in no way be construed to be a waiver of any such provision, nor in any way to affect the validity of this Agreement
or any part thereof or the right of any PARTY thereafter to enforce each and every such provision. No waiver of any breach of this Agreement shall be held to be a waiver of any other or subsequent breach. 

 

	13.3	All notices or other communications required or permitted hereunder with regard to the interpretation, validity etc. of the Agreement shall be in writing and shall be given by certified mail addressed, if to VIEWRAY:

 ViewRay Incorporated 

2000 Auburn Drive 

Beachwood, OH 44122 
 USA 

Attn: Chief Executive Officer 

and, if to SIEMENS: 
 Siemens
Aktiengesellschaft 
 Legal 

Werner-von-Siemens-Str. 50 

91052 Erlangen 
 Germany 

or to such other address that the PARTIES might identify to each other for this purpose and with reference to this Agreement. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	13.4	No PARTY hereto shall issue any press release or public announcement or otherwise divulge the existence of this Agreement or the transactions contemplated hereby without the prior approval of the other PARTY hereto.

  

	13.5	This Agreement shall be binding upon and inure to the benefit of the PARTIES hereto. Neither PARTY may assign this Agreement, in whole or in part, except with the prior written consent of the other PARTY, which shall
not be unreasonably withheld; provided, that either PARTY may assign this Agreement without the consent of the other PARTY to an Affiliate or in connection with any merger, acquisition, or sale a majority of such PARTY’s voting stock or
a sale of substantially all such PARTY’s assets; provided, further, that (a) in each instance the assignee expressly assumes all obligations imposed on the assigning PARTY by this Agreement in writing and the other PARTY is
notified in advance of such assignment; and (b) VIEWRAY shall also be subject to the restriction set forth in Article 9. Any purported assignment in violation of this Article 13.5 shall be null and void. 

 

	13.6	Titles and headings to Articles herein are inserted for the convenience or reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement. 

 

	13.7	This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement. 

  

	13.8	This Agreement (including the Appendices) constitutes the entire agreement between the PARTIES with respect to its subject matter and supersedes all prior agreements, understandings, commitments, negotiations and
discussions with respect thereto, whether oral or written. 

  

	13.9	During the term of this Agreement and for a period of 12 months thereafter, neither PARTY will not solicit for employment (whether as an employee, contractor, consultant, or in any other manner) any person who is
or has been within the previous 12 months a technical or scientific employee of the other PARTY; provided, however, that this Article 13.9 will not prevent either PARTY from employing a person who contacts such PARTY on his or her own
initiative (without any actions by such PARTY to encourage such contact) or responds to general solicitations of employment not specifically directed toward the other PARTY’S employees. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 IN WITNESS WHEREOF the PARTIES have executed these presents on the dates specified below. 

 

									
	VIEWRAY Incorporated	  		  	SIEMENS Aktiengesellschaft, Healthcare Sector
					
	Place, Date:	  		  	Place, Date	  		  	
					
	Cleveland, OH, USA 17 June 08	  		  	Erlangen, May 29 2008	  		  	
					
	/s/ Ayers	  		  	/s/ Mãrzendorfer	  		  	/s/ Kleinschmidt
					
	Name:	  		  	Name:	  		  	Name:
					
	Ayers	  		  	Mãrzendorfer	  		  	Kleinschmidt
	(Print)	  		  	(Print)	  		  	(Print)
					
	Title:	  		  	Title:	  		  	Title:
					
	CEO	  		  	CEO Magnetic Resonance	  		  	CFO Magnetic Resonance

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Appendix 0 

to the Collaboration and Supply Agreement between VIEWRAY and SIEMENS 

Data Sheet of [***] 
 The officially released data sheet
by SIEMENS at the time of signature of this Agreement is identified by the following SIEMENS document number. 
 [***] 

Status: 03/2008 
 A copy of the document will be provided to
VIEWRAY in an electronic format. 
 The [***], as modified in [***] will [***] the following [***]: 

 

	1)	The [***] on the [***] it to the [***] at a [***] that allows for [***] less than [***] based on [***] 

  

	2)	The [***] with a [***] and a [***] covering a [***] (corresponding to a [***]) within [***] having [***] that [***] may be [***] (i.e. . a [***]). 

 

	3)	The [***] covering a [***] with a [***] (corresponding to a [***] at a [***] (i.e. . a [***]). 

  

	4)	The [***] of all [***] must be [***] (i.e., the [***] must be able to [***] to within [***]). 

  

	5)	The [***] of all [***] must be [***] than [***] (i.e., the [***] must be [***] with this [***] with the [***]). 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Appendix 1 

to the Collaboration and Supply Agreement between VIEWRAY and SIEMENS: 

Reimbursement of SIEMENS Costs during PHASE 1 AND 2 

VIEWRAY will reimburse SIEMENS for the supply of COMPONENTS and the development support during PHASE 1 and 2 as described below. 

 

	 	•	 	[***] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Appendix 2 

to the Collaboration and Supply Agreement between VIEWRAY and SIEMENS: 

SUPPLY AGREEMENT 
 by and
between 
 ViewRay, Incorporated 

a corporation duly organized and existing under the laws of OH, 

and having its registered seat 

in Beachwood, OH, 
 USA 

- hereinafter referred to as “BUYER” - 

and 
 Siemens
Aktiengesellschaft, Healthcare Sector 
 a corporation organized under the laws of 

the Federal Republic of Germany 

Berlin and Munich 
 - hereinafter
referred to as “SELLER” - 
 - BUYER and SELLER hereinafter referred to individually 

as “PARTY” or collectively as “PARTIES” - 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Preamble 

WHEREAS BUYER shall procure from SELLER products in the course of a long term cooperation; and 

WHEREAS, for their mutual benefit, the PARTIES seek to secure the supply, to improve the planning, to ensure delivery on time, to minimize the
respective stocks and to reduce the expenditures for the transaction of business. 
 NOW THEREFORE in consideration of the above, the PARTIES
agree to the following terms and conditions: 
  

	1.	Subject of the Agreement 

 Subject of this SUPPLY AGREEMENT is the
procurement of the COMPONENTS as described in Annex 1 hereto. 
  

	2.	Demand Planning and Purchase Orders 

  

	2.1	BUYER shall place purchase orders with SELLER covering his demand for three (3) months (hereinafter referred to as “SUPPLY PERIOD”). Such purchase orders shall be issued at least eight (8) weeks
before the beginning of the respective SUPPLY PERIOD. 

  

	2.2	Together with his purchase orders BUYER shall furnish to SELLER a forecast indicating his demand for the period of nine (9) months following the SUPPLY PERIOD. 

SELLER shall consider the forecasts when planning his production capacities. If SELLER does not object in writing within ten (10) Business
Days after receipt of the forecast, it will be deemed accepted by SELLER, and BUYER may assume that SELLER will accept purchase orders within this scope. 
  

	2.3	 BUYER shall forward his purchase orders in writing to SELLER’s relevant local subsidiary. SELLER shall
acknowledge the purchase orders within ten (10) Business Days after receipt thereof, as far as they do not exceed the forecast accepted by SELLER. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
SELLER shall make reasonable efforts to meet BUYER’s demand exceeding the forecast. In case SELLER can accept a purchase order of BUYER exceeding the forecast only with modifications (for
example concerning delivery date or quantity), the PARTIES will agree without delay on a mutually acceptable solution. 
  

	2.4	If subsequently to the acknowledgement of any purchase order BUYER requires an earlier or later delivery date as agreed, the PARTIES shall use best efforts to find a mutually acceptable solution. 

 

	2.5	The terms and conditions of this SUPPLY AGREEMENT shall apply to any purchase order of BUYER regarding the COMPONENTS even if they do not refer to it expressly. Any separate general terms and conditions of BUYER or
SELLER shall not apply. 

  

	2.6	“Business Day” means any day other than a Saturday or Sunday that is not a national holiday in the United States or Germany. 

 

	3.	Delivery 

  

	3.1	The COMPONENTS are delivered “EXW” according to Incoterms 2000. 

  

	3.2	If the delivery date is defined 

  

	 	(a)	by day, SELLER shall not deliver more than three (3) days earlier or later as the agreed delivery day; 

  

	 	(b)	by week, SELLER shall deliver within the agreed delivery week. 

  

	3.3	In case SELLER realizes that he cannot adhere to the agreed delivery date, he shall without delay inform BUYER and indicate the prospective duration of the delay. The PARTIES shall immediately endeavor to find
reasonable remedial measures. 

  

	3.4	If SELLER is in delay with deliveries for which he is responsible and if BUYER substantiates that he has suffered damages due to the delay, he may claim per full week of delay liquidated damages of 0.5% of the price of
the delayed COMPONENTS up to a maximum amount of 5% of such price. Any further claims for damages due to the delay shall be excluded. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Further, BUYER may cancel the relevant separate purchase contract without incurring any
liability, provided the COMPONENTS have not been delivered within a reasonable grace period set by BUYER. 
  

	4.	Prices 

  

	4.1	The prices of the COMPONENTS are specified in Annex 2 hereto and are valid for the agreed upon time period. 

  

	4.2	The prices are based on the clause of the Incoterms 2000 as defined in Section 3.1 and include packaging. The respectively valid VAT shall be added to the price. 

 

	5.	Invoices and Terms of Payment 

  

	5.1	SELLER shall issue for every delivery an invoice meeting the requirements of the tax laws. The invoice shall show the price per ordered COMPONENTS, the order number and the COMPONENTS part number. 

 

	5.2	Payments shall be effected in EURO within 30 days from the invoice date. 

  

	6.	Risk, Title 

  

	6.1	Risk of loss or damages shall pass onto BUYER according to the clause of the Incoterms 2000 as defined in Section 3.1. 

  

	6.2	SELLER retains title to the COMPONENTS until all payments due to SELLER have been finally effected by BUYER. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	7.	Warranty, Services, Spare Parts 

  

	7.1	SELLER assumes liability for defects of the COMPONENTS including the lack of assured characteristics as follows: 

SELLER shall at its sole discretion either repair or replace the faulty COMPONENTS. In case these corrective actions fail within a reasonable
period of time, BUYER is entitled to request price reduction or to cancel the relevant purchase contract and request SELLER to take back the COMPONENTS delivered (under such purchase contract) and to reimburse the purchase price. 

Details will be described in the Quality Assurance Agreement as per Annex 4 to the SUPPLY AGREEMENT. 

 

	7.2	The warranty period for COMPONENTS shall be 15 months starting on the date the risk of loss or damage has passed onto BUYER according to Section 6.1 or 12 months from the date of installation at customer
site, whichever is the earlier. 

  

	7.3	SELLER will be able to supply spare parts for the COMPONENTS for the period of 8 (eight) years after the last delivery of COMPONENTS. 

 

	7.4	SELLER’s liability for any further damages resulting from the defect(s) of the COMPONENTS shall be limited pursuant to the stipulations of Section 12. 

 

	7.5	The SELLER shall, at SELLER’s then current pricing, provide the BUYER with information (e.g. service training courses, service documentation, etc.) and aids (e.g. tools, software, etc) to enable the BUYER to
perform the service function. Details on the aforesaid are to be found in Annex 3 hereto. 

  

	7.6	The BUYER is only entitled to use the information and aids within its own service organization and only to perform services on COMPONENTS that were purchased by the BUYER under this SUPPLY AGREEMENT and delivered to
end-users. The transfer of information and/or aids to third PARTIES will be subject to prior written approval by the SELLER. 

  

	7.7	The SELLER shall provide the BUYER with spare parts for the COMPONENTS at SELLER’s then current prices during the term of this Agreement and for a period of eight (8) years after delivery of the last PRODUCT
pursuant to this agreement. Details of the processing of spare parts and returned goods are to be found in Annex 3 hereto. The provisions governing the COMPONENTS shall also apply to spare parts unless agreed otherwise in this agreement.

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	8.	Technical Changes 

  

	8.1	SELLER is entitled to technically change the COMPONENTS without notice to BUYER; provided that the COMPONENTS continue to conform to the applicable specifications for the then-current COMPONENTS. Notwithstanding the
foregoing, SELLER shall notify BUYER about the changes in writing at least three (3) months before start of production of the changed COMPONENTS. If SELLER makes technical changes to the COMPONENTS that will cause them to not conform to the
applicable specifications for the then-current COMPONENTS then SELLER shall follow the procedure in Section 8.2. 

  

	8.2	 If SELLER intends to discontinue the production of then-current COMPONENTS in favor of new COMPONENTS or to make
technical changes to the then-current COMPONENTS that SELLER reasonably expects to affect form, size, assembly, function or interfaces of the COMPONENTS so that such new or changed COMPONENTS fail to conform to the applicable specifications for the
then-current COMPONENTS, SELLER shall as early as reasonably practicable, taking into consideration the regulatory requirements of introducing changes to the then-current COMPONENTS and the MRgRT System notify BUYER and give BUYER access to
specifications for the “new” COMPONENTS as well as access (at SELLER’S facility—or at BUYER’s request and expense at Buyer’s Beachwood, Ohio facility) to a preproduction prototype of the new COMPONENTS prior to
commercial release of the new COMPONENTS to permit BUYER to test the COMPONENTS and provide input to SELLER on its impact on the MRgRT System. BUYER will notify SELLER not later than 3 months following the date it is notified of such technical
changes by SELLER whether BUYER will adopt the new COMPONENTS for use in the MRgRT System. If BUYER adopts the new COMPONENTS for use in the MRgRT System, Annex 1 and, to the extent applicable, Annex 2 will be amended to reflect the new
COMPONENTS. If BUYER has not yet adopted the new COMPONENTS for use in the MRgRT System and 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
SELLER decides to discontinue production of the then-current COMPONENTS, BUYER may, in order to cover its remaining demand, place purchase orders in accordance with Sections 2.1 and 2.4 for
the unchanged then-current COMPONENTS within 3 months after being notified about the technical changes by SELLER. 
  

	8.3	BUYER may request that SELLER incorporate changes to the COMPONENTS going forward by delivering a written change order to SELLER (a “Post-Development Change Order”). Any such Post-Development Change Order will
include a description of the proposed change sufficient to permit SELLER to evaluate its feasibility and cost. SELLER will use reasonable efforts to provide within 15 Business Days of receipt of a Post-Development Change Order a detailed
response to the Post-Development Change Order including a specification of: (a) new material costs; (b) new labor cost itemized by activity to be performed; (c) the proposed implementation date; and (d) the impact on the delivery
schedule and pricing of the COMPONENTS. SELLER will not unreasonably withhold or delay agreement to a Post-Development Change Order. Until a Post-Development Change Order has been agreed to in writing, such Post-Development Change Order will not
become effective, and the PARTIES will continue to perform their obligations under the then-effective specifications. 

  

	9.	Discontinuance of Production 

 Should SELLER plan to discontinue the production of
COMPONENTS, of which BUYER has procured from SELLER any substantial amount within the preceding 12 months, SELLER shall inform BUYER in writing at least 6 months prior to the date production of such COMPONENTS shall discontinue. BUYER may, in
order to cover its remaining demand, place orders in accordance with Section 2.4 until 3 months before the discontinuance date specified in SELLER’s notice, which date shall be at least 6 months following the date of such notice
to BUYER. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	10.	Industrial and Intellectual Property Rights 

  

	10.1	If a third PARTY raises justified claims against BUYER for infringement of intellectual property rights or copy rights (all together hereafter referred to as “Protective Rights”) by COMPONENTS supplied by
SELLER, SELLER shall at its cost acquire for BUYER a right to use the COMPONENTS. In case this is not possible at economically reasonable conditions, SELLER’s liability shall be limited as follows: 

 

	 	(a)	SELLER shall defend and indemnify and hold harmless BUYER against any legal costs and damages of BUYER caused by Protective Right infringement by the COMPONENTS as such up to the amount of an appropriate license fee,
which the owner of the Protective Rights could claim directly from SELLER for the use of the infringing COMPONENTS. 

  

	 	(b)	For future deliveries SELLER shall, if economically reasonable, at its option and in compliance with the specifications defined in Annex 1 modify the COMPONENTS to become non-infringing or deliver an equivalent non
infringing COMPONENTS. 

 Claims shall be deemed justified only if they are acknowledged as such by SELLER or finally
adjudicated as such by a court of competent jurisdiction. 
  

	10.2	The obligations of SELLER mentioned in Section 10.1 above apply under the precondition that BUYER informs SELLER without delay in writing of any claims for infringement of Protective Rights, does not accept on his
own any such claims and conducts any disputes, including settlements out of court, only in agreement with SELLER. 

  

	10.3	Any liability of SELLER pursuant to Section 10.1 shall be excluded, if the infringement of Protective Rights is not caused by the COMPONENTS itself, for example if such infringement results from the application of
the COMPONENTS (including any application-specific circuitry implemented in the COMPONENTS), unless SELLER did offer the COMPONENTS especially for such infringing application. 

 

	10.4	Any liability of SELLER shall also be excluded, if the infringement of Protective Rights results from specific instructions given by BUYER or the fact that the COMPONENTS has been changed by BUYER or is being used in
conjunction with products not delivered by SELLER, which convert an otherwise non-infringing COMPONENTS to an infringing COMPONENTS. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	11.	Confidential Information 

  

	11.1	The PARTIES shall use all information, which they receive in connection with this SUPPLY AGREEMENT and which has been marked as confidential, only for the purposes of this SUPPLY AGREEMENT and they shall keep this
information confidential to third PARTIES with the same degree of care as they use with respect to their own confidential information. This obligation shall survive the expiration or termination of this SUPPLY AGREEMENT for a period of 3 years.

  

	11.2	This obligation shall not apply to information, which is or becomes public knowledge or which is provably independently developed or lawfully received from a third PARTY. 

 

	12.	Liability 

  

	12.1	SELLER assumes liability for any personal injury for which it is found responsible without limitation. If found responsible for property damages of BUYER, SELLER shall indemnify BUYER for expenses incurred for
restoration of the damaged property up to a maximum amount of EURO 500.000 per damage event and EURO 1.500.000 in the aggregate. 

  

	12.2	Apart from warranties and liabilities expressly stipulated in this SUPPLY AGREEMENT, SELLER disclaims all liability regardless of the cause in law, in particular the liability for indirect or consequential damages
arising from interrupted operation, loss of profits, loss of information and data, unless in cases of gross negligence, intent, lack of assured characteristics or in any cases where liability is mandatory at law. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	13.	Term, CHANGE OF CONTROL and Exclusivity 

  

	13.1	(a) This SUPPLY AGREEMENT shall be effective from the EFFECTIVE DATE II and shall run for an initial period of five (5) years unless sooner terminated in accordance with Section 13.1(b). Thereafter,
unless terminated by either PARTY effective at the end of each calendar year upon six (6) months prior written notice, this SUPPLY AGREEMENT will be automatically extended by twelve (12) months. 

 

	 	(b)	Either PARTY may, without prejudice to any other rights it may have, terminate this SUPPLY AGREEMENT by providing written notice to the other PARTY if the other PARTY breaches any of its representations, warranties or
obligations under this SUPPLY AGREEMENT and fails to cure such breach within 60 days after receiving written notice thereof from the non-breaching PARTY. 

  

	 	(c)	For a period of six months after expiration or termination of this SUPPLY AGREEMENT for any reason, SELLER will provide reasonable assistance (at Buyer’s expense) to wind-down the supply of COMPONENTS for
BUYER’s MRgRT System. This cooperation will include. (i) the continued manufacture and orderly supply of COMPONENTS after the termination or expiration date, provided that in the event that the termination was effected by SELLER as a
result of BUYER’s material breach of this SUPPLY AGREEMENT, BUYER will promptly pay all sums due SELLER under this SUPPLY AGREEMENT (other than those that are disputed in good faith by BUYER) as of the date of termination; (ii) continued
support of COMPONENTS in accordance with the terms of this SUPPLY AGREEMENT after the termination or expiration date, provided that in the event that the termination was effected by SELLER as a result of Buyer’s material breach of this SUPPLY
AGREEMENT BUYER will promptly pay all sums due SELLER under this SUPPLY AGREEMENT (other than those that are disputed in good faith by BUYER) as of the date of termination; and (iii) the right to make a last time buy of COMPONENTS, provided
that in the event that the termination was effected by SELLER as a result of Buyer’s material breach of this SUPPLY AGREEMENT BUYER will promptly pay all sums due SELLER under this SUPPLY AGREEMENT (other than those that are disputed in good
faith by BUYER) as of the date of termination. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	 	(d)	On termination or expiration of this SUPPLY AGREEMENT for any reason BUYER will have the right to continue to sell all unsold COMPONENTS that are in its possession or that are subject to an open BUYER bid and purchase
order as of the effective date of such termination or expiration. 

  

	 	(e)	After the termination or expiration of this SUPPLY AGREEMENT, at Buyer’s request, SELLER will continue to provide support services to BUYER for installed COMPONENTS under the terms and conditions set forth in this
SUPPLY AGREEMENT at SELLER’S then-standard rates during the remaining term of Buyer’s purchase agreements with its end users. BUYER will continue to support such end users in the same manner that BUYER provides similar support for other
elements of the MRgRT System. 

  

	13.2	For the duration of this SUPPLY AGREEMENT, but not exceeding seven (7) years-from EFFECTIVE DATE II (as defined in Article 4.1 of the Development and Supply Agreement dated May __, 2008 between the PARTIES),
SELLER shall be the exclusive supplier of COMPONENTS and BUYER shall not source any 3rd PARTY spectrometer for the MRgRT System. 

  

	13.3	 If BUYER obligates itself with respect to a CHANGE OF CONTROL with a third party that is an “INDIRECT
COMPETITOR” of SELLER during the term of this SUPPLY AGREEMENT, the PARTIES will discuss in good faith within thirty (30) days after such CHANGE OF CONTROL is publicly announced, how such CHANGE OF CONTROL would impact the relationship
contemplated by this SUPPLY AGREEMENT, including whether BUYER or such INDIRECT COMPETITOR will terminate this Agreement after the closing of such CHANGE OF CONTROL transaction. SELLER shall be entitled to terminate this SUPPLY AGREEMENT within a
period of thirty (30) days following the receipt of such a notification and discussion if it is not reasonably assured that such CHANGE OF CONTROL will not adversely affect the prospects for commercial success of the transactions contemplated
by this SUPPLY AGREEMENT. With respect to a CHANGE OF CONTROL involving a “DIRECT COMPETITOR”, SELLER shall be entitled to terminate this SUPPLY AGREEMENT within a period of thirty (30) days

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
following the receipt of such a notification at its own discretion. For purposes of this SUPPLY AGREEMENT, “DIRECT COMPETITOR” means an entity that has an MRI product line. As of the
Effective Date I, DIRECT COMPETITORS may include each of GE Healthcare, Hitachi Medical Systems Corporation, Toshiba Medical Systems Corporation and Philips Healthcare or their respective affiliates. For purposes of this SUPPLY AGREEMENT,
“INDIRECT COMPETITOR” means an entity that is not a DIRECT COMPETITOR but which has a product line that competes with another product line of SIEMENS. 
  

	13.4	BUYER may terminate this SUPPLY AGREEMENT within thirty (30) days following the date a CHANGE OF CONTROL involving a DIRECT COMPETITOR or INDIRECT COMPETITOR is publicly announced, In case of termination of this
SUPPLY AGREEMENT by BUYER following a CHANGE OF CONTROL involving a DIRECT COMPETITOR or INDIRECT COMPETITOR, BUYER shall reimburse SELLER for lost revenue. This includes the complete payment of all outstanding purchase orders of COMPONENTS and
equipment rental as well as engineering and application support services. Any remaining forecast revenue value arising from this SUPPLY AGREEMENT will be reimbursed by BUYER at a value of thirty (30) percent of the agreed purchasing price of
the COMPONENTS for the forecast period of twelve (12) months from the date such CHANGE OF CONTROL is publicly announced. 

  

	13.5	In case of termination of this SUPPLY AGREEMENT by SELLER in accordance with Section 13.3, SELLER will not have a right of any compensation for lost revenue pursuant to Section 13.4. 

 

	13.6	 “CHANGE OF CONTROL” means with respect to BUYER, in an event or series of related events: (a) a
sale of all or substantially all of BUYER’s assets, voting stock or securities or business relating to this SUPPLY AGREEMENT; (b) a merger, reorganization or consolidation involving BUYER in which the stockholders of BUYER immediately
prior to such transaction cease to own collectively a majority of the voting equity securities of the successor entity; or (c) a Person or group of Persons acting in concert acquire fifty percent (50%) or more of the voting equity
securities of BUYER. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
For purposes of clarity, the term “CHANGE OF CONTROL” is not intended to include (i) an underwritten public offering of BUYER’s common stock pursuant to a Registration
Statement on Form S-1 under the Securities Act of 1933, as amended, or (ii) any sale of shares of capital stock of BUYER, in a single transaction or series of related transactions principally for bona fide equity financing purposes in
which BUYER issues new securities to venture capital investors primarily for cash or the cancellation or conversion of indebtedness of BUYER or a combination thereof for the purpose of financing the operations and business of BUYER. 

 

	13.7	The provisions in Sections 7, 10, 14, 15 shall survive the expiration or termination of this agreement. Any licenses granted by SELLER to BUYER under this SUPPLY AGREEMENT or the AGREEMENT will survive any
expiration or termination of this SUPPLY AGREEMENT for any reason for as long as and to the extent that they are reasonably necessary to continue servicing and supporting existing accounts. 

 

	14.	Arbitration 

  

	14.1	All disputes arising out of or in connection with this SUPPLY AGREEMENT or individual purchase contracts signed hereunder, including any question regarding their existence, validity or termination, shall be finally
settled under the Rules of Arbitration of the International Chamber of Commerce, Paris (“Rules”) by three arbitrators in accordance with the said Rules. 

 

	14.2	Each PARTY shall nominate one arbitrator for confirmation by the competent authority under the applicable Rules (“Appointing Authority”). Both arbitrators shall agree on the third arbitrator within
30 days. Should the two arbitrators fail within the above time-limit to reach agreement on the third arbitrator, he shall be appointed by the Appointing Authority. 

 

	14.3	The seat of arbitration shall be Zurich. The procedural law of this place shall apply where the Rules are silent. 

  

	14.4	The language to be used in the arbitration proceeding shall be English. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	14.5	Any claim, controversy or dispute between the PARTIES arising in whole or in part under or in connection with this SUPPLY AGREEMENT or the subject matter hereof will, before such submission to arbitration, first be
escalated to the MRI Business Unit Chief Executive Officer of SELLER and the Chief Executive Officer of BUYER for resolution. They will use reasonable efforts to attempt to resolve the dispute through good faith negotiations by telephone or in
person as may be agreed and if they fail to resolve the dispute within thirty (30) days after either party notifies the other of the dispute, and do not mutually agree to extend the time for negotiation, then the dispute will be submitted to
arbitration in accordance with the procedure set forth in Sections 14.1-14.4. 

  

	15.	Applicable Law 

 This SUPPLY AGREEMENT and individual purchase contracts signed between
the PARTIES hereunder shall be governed by and construed in accordance with the law in force in Switzerland without reference to its conflicts of law provisions. The application of the United Nations Convention on Contracts for the International
Sale of Goods of April 11, 1980 shall be excluded. 
  

	16.	Miscellaneous 

  

	16.1	Alterations and amendments to this SUPPLY AGREEMENT shall only be valid if made in writing and signed by an authorized representative of each PARTY. 

 

	16.2	The effectiveness of this SUPPLY AGREEMENT shall not be impaired if any provision of this SUPPLY AGREEMENT should be completely or partially invalid or unenforceable. In this case, the PARTIES shall agree on a
provision, that meets the economical intention of the invalid or unenforceable provision. 

  

	16.3	The failure of any PARTY hereto to enforce at any time any of the provisions of this SUPPLY AGREEMENT shall in no way be construed to be a waiver of any such provision, nor in any way to affect the validity of this
SUPPLY AGREEMENT or any part thereof or the right of any PARTY thereafter to enforce each and every such provision. No waiver of any breach of this SUPPLY AGREEMENT shall be held to be a waiver of any other or subsequent breach. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	16.4	All notices or other communications required or permitted hereunder with regard to the interpretation, validity etc. of the SUPPLY AGREEMENT shall be in writing and shall be given by certified mail addressed, if to
BUYER: 

 ViewRay Incorporated 

2000 Auburn Drive 

Beachwood, OH 44122 
 USA 

Attn: Chief Executive Officer 

and, if to SELLER: 
 Siemens
Aktiengesellschaft 
 Legal 

Werner-von-Siemens-Str. 50 

91052 Erlangen 
 Germany 

or to such other address that the PARTIES might identify to each other for this purpose and with reference to this SUPPLY AGREEMENT. 

 

	16.5	No PARTY hereto shall issue any press release or public announcement or otherwise divulge the existence of this SUPPLY AGREEMENT or the transactions contemplated hereby without the prior approval of the other PARTY
hereto. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	16.6	This SUPPLY AGREEMENT shall be binding upon and inure to the benefit of the PARTIES hereto. Neither PARTY may assign this SUPPLY AGREEMENT, in whole or in part, except with the prior written consent of the other PARTY,
which shall not be unreasonably withheld; provided, that either PARTY may assign this SUPPLY AGREEMENT without the consent of the other PARTY to an Affiliate or in connection with any merger, acquisition, or sale a majority of such
PARTY’s voting stock or a sale of substantially all such PARTY’s assets; provided, further, that (a) in each instance the assignee expressly assumes all obligations imposed on the assigning PARTY by this SUPPLY AGREEMENT
in writing and the other PARTY is notified in advance of such assignment; and (b) BUYER shall also be subject to the restriction set forth in Sections 13.3-13.6. Any purported assignment in violation of this Section 16.6 shall be null
and void. 

  

	16.7	Titles and headings to Sections herein are inserted for the convenience or reference only and are not intended to be a part of or to affect the meaning or interpretation of this SUPPLY AGREEMENT. 

 

	16.8	This SUPPLY AGREEMENT may be executed in one or more counterparts, all of which shall be considered one and the same agreement. 

  

	16.9	This SUPPLY AGREEMENT constitutes the entire agreement between the PARTIES with respect to its subject matter and supersedes all prior agreements, understandings, commitments, negotiations and discussions with respect
thereto, whether oral or written. This SUPPLY AGREEMENT is an Appendix to the Development and Supply Agreement dated May     , 2008 between the PARTIES and in the event of any conflict between the terms of this SUPPLY
AGREEMENT and the terms of the Development and Supply Agreement, such conflict will be resolved in accordance with Article 4.1 of the Development and Supply Agreement. 

 

	16.10	 If either PARTY’s performance under this SUPPLY AGREEMENT is prevented, restricted or interfered with by
reason of acts of God, wars, revolution, civil commotion, acts of public enemy, labor strikes (other than employees of the affected PARTY), terrorism, embargo or acts of government in its sovereign capacity (Force Majeure”), the

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
“affected PARTY” will, after giving prompt notice to the other PARTY, be excused from such performance on a day-to-day basis during the continuance of such prevention, restriction, or
interference (and the other PARTY will likewise be excused from performance of its obligations on a day-to-day basis during the same period), provided, however, that the affected PARTY will use its best efforts to avoid or remove the causes of
nonperformance and both PARTIES will proceed immediately with the performance of their obligations under this SUPPLY AGREEMENT whenever the causes are removed or cease. If Force Majeure conditions continue for more than 90 consecutive days or an
aggregate 120 days in any 12-month period, then the disadvantaged PARTY (but not the affected PARTY) may terminate this SUPPLY AGREEMENT. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

			
	 Annex 1:
	  	Specification of COMPONENTS (Section 1)
		
	 Annex 2:
	  	Price List (Section 4)
		
	 Annex 3:
	  	Service Requirements
		
	 Annex 4:
	  	Quality Assurance Agreement

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Annex 1 
 to
the SUPPLY AGREEMENT between BUYER and SELLER 
 Specification of COMPONENTS 

SIEMENS commits to supply the following COMPONENTS to BUYER, based upon the SELLER [***]: 

 

	 	a.	[***] 

 The following items are not included in the COMPONENTS: [***]. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Annex 2 
 to
the SUPPLY AGREEMENT between BUYER and SIEMENS 
 Price List 
  

	1.	Prices for PRODUCTS 

  

	1.1	The price shall be EXW (Incoterms 2000), including packaging. The prices are valid until September 30, 2010. Prior to the end of that period Supplier shall inform Purchaser giving at least three (3) months
notice about price changes becoming effective after such period. 

  

							
	 Item
	  	 Equipment
	  	 Units
per year
	  	 Price
per unit
in EUR

	 [***]
	  	[***]	  	[***]	  	[***]

  

	1.2	The price shall be net, fixed in EUR. Any fiscal charges, taxes, etc., that arise be listed separately. 

  

	1.3	In general, the unit price shall be charged. 

  

	1.4	The contractually agreed annual delivered quantity shall be considered for the unit price for graduated prices based on volume. 

  

	1.5	If the quoted price depends on the volume of the actually delivered quantity, the lower price as compared to the smallest quantity for the fiscal year just ended (October 1 until September 30) shall be
retrospectively determined and settled through an annual invoice. Payment shall be affected within 90 days upon receipt of the invoice, however, not prior to payment of all deliveries within the accounting period. 

 

	2.	Payments shall be considered made, when the amount has been posted on the agreed account of the SUPPLIER. The PRODUCTS shall remain the property of the SUPPLIER until they have been fully paid. 

 

	3.	Invoices shall be paid within 30 calendar days from the date of the invoice. 

  

	4.	The prices for SPARE PARTS are the Siemens customer list price (CLP) minus [***]. 

 Unless the
Contracting Parties agree otherwise, the above regulations for PRODUCTS shall equally apply to SPARE PARTS. 

  
 [***] Two pages in this document have
been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Annex 3 
 to
the SUPPLY AGREEMENT between BUYER and SELLER 
 SERVICE 

This Annex 3 shall regulate service topics, such as: 
  

	 	•	 	Spare parts supply and logistics 

  

	 	•	 	Service contracts (between the PARTIES and (to the extent applicable) with customers. 

  

	 	•	 	First, second and third level service support (and which PARTY shall be responsible for each level of support. 

  

	 	•	 	Software and computer hardware upgrades for the installed base 

  

	 	•	 	Training of BUYER personnel (to the extent appropriate for the support responsibilities assumed by BUYER). 

  

	 	•	 	Recalls and Field Support for damaged or defective COMPONENTS installed at customer sites. 

 BUYER and SELLER
shall mutually agree upon the contents of this Annex 3 not later than thirty (30) days after commencement of PHASE 3 and in the event the PARTIES are unable to reach agreement on any such matter they shall resolve such disagreement
using the procedure specified in Section 14 of the SUPPLY AGREEMENT. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Annex 4 
 to
the SUPPLY AGREEMENT between VIEWRAY and SIEMENS 
 Quality Agreement will require a separate signature between both PARTIES, since such Quality Agreement
will be revision controlled. The following Quality Agreement can only be considered as a guide line. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Quality Assurance Agreement 

by and between 
 ViewRay,
Incorporated 
 a corporation duly organized and existing under the laws of OH, 

and having its registered seat 
 in
Beachwood, OH, 
 USA 
 –
hereinafter referred to as “BUYER” – 
 and 

Siemens Aktiengesellschaft, Healthcare Sector 

a corporation organized under the laws of 

the Federal Republic of Germany 

Berlin and Munich 
 –
hereinafter referred to as “SELLER” – 
 - BUYER and SELLER hereinafter referred to individually 

as “PARTY” or collectively as “PARTIES” - 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Quality Assurance Agreement 

Between VIEWRAY and SIEMENS 
  

 Contents 
  

							
	Contents	  	 	43	  
	History	  	 	43	  
	[***]-QUALITY ASSURANCE AGREEMENT	  	 	44	  
	Annex 1	  	 	46	  
	         1
	  	Scope	  	 	46	  
		
	Annex 2	  	 	47	  
	         2.1
	  	Requirements Placed on the SELLER’s Quality Management System	  	 	47	  
	         2.2
	  	Obligation to Keep Records and Archiving	  	 	47	  
	         2.3
	  	Verifying the QM system	  	 	48	  
	         2.4
	  	Additional QM System requirements	  	 	48	  
	         2.4.1
	  	Quality Management for New Products	  	 	48	  
	         2.4.2
	  	Quality Management in the Case of Repairs of Used Products	  	 	50	  
	         2.4.3
	  	Storage, Packaging and Transport	  	 	50	  
	         2.4.4
	  	Product Risk Analysis	  	 	51	  
		
	Annex 3	  	 	52	  
	         3.1
	  	Corrective and Preventative Measures	  	 	52	  
	         3.2
	  	Complaints	  	 	52	  
		
	Annex 4	  	 	53	  
	         4.1
	  	Incoming Inspection by the BUYER	  	 	53	  
	         4.2
	  	Quality Assurance Representative	  	 	53	  
	         4.3
	  	Exchange of Quality-relevant information via E-mail	  	 	54	  

 History 
  

									
	 Version
	  	Created	  	 Author, Dept.
	  	 Changes
	  	 Valid from

	 1.0
	  	16.05.08	  	[***]	  	n.a.	  	01.06.08

  

  

											
	Initials:	  	  
	  	  
	  	Initials:	  	  
	  	  

		  	(Date)	  	(Purchaser)	  		  	(Date)	  	(Purchaser)
						
	Version:	  	            <  >	  		  	Valid from:	  	            <Date>	  	

 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

			
	 [***]
	  	•

  
 [***] Two pages in this document have
been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Quality Assurance Agreement 

Between VIEWRAY and SIEMENS 
  

 Annex 1 
  

	1.	Scope 

 This Quality Assurance Agreement applies to the following COMPONENTS delivered by the SELLER
to the BUYER: 
  

	 	a.	[***] 

 This Quality assurance Agreement also applies to spare parts for the aforementioned COMPONENTS, which
are delivered by the SELLER to the BUYER’s Customer Services. These spare parts may also be sub-components of the delivered products and, depending on the BUYER’s order, may consist of new or repaired goods. 

  

											
	Initials:	  	  
	  	  
	  	Initials:	  	  
	  	  

		  	(Date)	  	(Purchaser)	  		  	(Date)	  	(Purchaser)
						
	Version:	  	            <_>	  		  	Valid from:	  	            <Date>	  	

 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Quality Assurance Agreement 

Between VIEWRAY and SIEMENS 
  

 Annex 2 
  

	2.	DO NOT DELETE 

  

	2.1	Requirements Placed on the SELLER’s Quality Management System 

 The SELLER maintains a quality
management system (hereinafter referred to as the “QM System”) that meets the following requirements: 
  

			
	 Standard:
	  	 Certifying office:

	 [***]
	  	[***]

 The SELLER shall inform the BUYER without undue delay of [***]. 

 

	2.2	Obligation to Keep Records and Archiving 

 The SELLER shall prepare documentation that describes both the
[***] and the [***]. Changes of products and processes] as part of the [***] are described in the [***] and are also [***] of [***]. 
 [***] are to be
[***] for at least [***] of the [***]. 
 The SELLER shall [***] of the [***]. Such documentation [***], in relation to the [***] as well as the [***] for
each [***], including the [***] in the [***]. 
 All [***] are to be [***] for at least [***] of the [***]. 

[***] are to be [***] in a [***] and, if required, are to be [***] to the [***] within a maximum period of [***]. 

Following [***] of the [***], the SELLER shall [***] to the BUYER. 

The provisions about [***] of this Quality Assurance Agreement. 

  

											
	Initials:	  	  
	  	  
	  	Initials:	  	  
	  	  

		  	(Date)	  	(Purchaser)	  		  	(Date)	  	(Purchaser)
						
	Version:	  	            <_>	  		  	Valid from:	  	            <Date>	  	

 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Quality Assurance Agreement 

Between VIEWRAY and SIEMENS 
  

	2.3	Verifying the QM system 

 The right of the BUYER described in Section III,
sub-section 1, of the [***] Quality Assurance Agreement, namely to verify the adherence to the agreed quality assurance measures contains the right to [***] and to [***] by the Seller. The checks may be carried out by way of [***] (e.g. [***]
involving the [***]) and via [***]. 
 The [***] my also be done by the [***] for the BUYER according to the [***] or authorized organization or by
third PARTIES commissioned by the BUYER. 
  

	2.4	Additional QM System requirements 

  

	2.4.1	Quality Management for New Products 

 New products may only contain components drawn from used products
if the expressly approved by BUYER. 
 The SELLER undertakes to [***]. If [***] is agreed upon for products or components of such products, such as [***],
the SELLER shall provide [***] as part of the [***]. To [***] SELLER shall [***] that relate to [***] or get the respective [***] from its [***]. 
 The
SELLER is responsible for the [***] and the [***] including the [***] of the [***]. 
 The SELLER ensures that the [***] in accordance with the [***]. This
means, among other things, the [***] are used [***] and that a [***] ensures that these [***]. 
 To provide proof that the [***], the SELLER ensures that
the [***] as well as [***]. The tests must be carried out in accordance with [***] in accordance with the [***] at time of testing. The SELLER shall [***] in accordance with [***], e.g. by way of a [***]. 

The SELLER shall ensure that [***] that do not [***]. 
  

	 	•	 	In the case products [***], the SELLER may [***] to the [***]. The following details are to be included in [***] 

The respective products are to be [labeled] so that they can [***]. Products that contain [***] by the BUYER. 

[***] is to be provided in relation to the [***] 

  

											
	Initials:	  	  
	  	  
	  	Initials:	  	  
	  	  

		  	(Date)	  	(Purchaser)	  		  	(Date)	  	(Purchaser)
						
	Version:	  	            <_>	  		  	Valid from:	  	            <Date>	  	

 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Quality Assurance Agreement 

Between VIEWRAY and SIEMENS 
  

	2.4.2	Quality Management in the Case of Repairs of Used Products 

 In the case of repairs of used products
([***]), to the extent applicable the [***]. 
 Repaired products must [***]. They must be [***]. 

 

	2.4.3	Storage, Packaging and Transport 

 Following the [***] shall ensure that [***] is given for [***] in
particular against [***]. 
 To the extent the PARTIES do not have any [***], the products shall be [***]. The SELLER shall [***], that there is [***] and
that the [***]. 
 As far as possible, the [***] by way of [***], the reduction of the [***] and use of [***] as well as the [***] are to be [***]. 

With regard to [***] are to be used that can [***] by way of a [***] and which are [***] with regard to [***]. The possibilities with regard to [***] the use
of [***] are to be utilized insofar as such course of action is [***]. 
  

	2.4.4	Product Risk Analysis 

 The [***], which enables him to [***]. The compliance with such [***]. 

[***] 

  

											
	Initials:	  	  
	  	  
	  	Initials:	  	  
	  	  

		  	(Date)	  	(Purchaser)	  		  	(Date)	  	(Purchaser)
						
	Version:	  	            <_>	  		  	Valid from:	  	            <Date>	  	

 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Quality Assurance Agreement 

Between VIEWRAY and SIEMENS 
  

 Annex 3 
  

	3.	DO NOT DELETE 

  

	3.1	Corrective and Preventative Measures 

 SELLER shall [***] and shall derive the [***] from this. [***] are
products that have [***] and products that have [***]. Every [***]. This means, in particular determining [***]. These [***] are to be coordinated with [***]. 

The data from the [***] 
  

	3.2	Complaints 

 If returned products are [***]), these parts are to be [***] 

In some cases the [***]. These products must be [***]. The [***] are to be made on a case by case basis between the [***]. 

  

											
	Initials:	  	  
	  	  
	  	Initials:	  	  
	  	  

		  	(Date)	  	(Purchaser)	  		  	(Date)	  	(Purchaser)
						
	Version:	  	            <  >	  		  	Valid from:	  	            <Date>	  	

 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Quality Assurance Agreement 

Between VIEWRAY and SIEMENS 
  

 Annex 4 

4. DO NOT DELETE 
  

	4.1	Incoming Inspection by the BUYER 

 [***] from Section IV Section 1 of the [***] Quality
Assurance Agreement the BUYER shall [***] whether the [***] thereof correspond to the [***] and whether there is any [***] that is [***] of the [***]. 

[***] that may apply may only be [***]. The SELLER shall be [***] 
  

	4.2	Quality Assurance Representative 

 Quality assurance representative/quality management officer of the
SELLER: 
  

			
	 Name:
	  	[***]
	 Dept:
	  	[***]
	 Telephone:
	  	[***]
	 Fax:
	  	[***]
	 E-mail:
	  	[***]

 Quality assurance representative/quality management officer of the BUYER: 

Name: 
 Dept: 

Telephone: 
 Fax: 

E-mail: 

  

											
	Initials:	  	  
	  	  
	  	Initials:	  	  
	  	  

		  	(Date)	  	(Purchaser)	  		  	(Date)	  	(Purchaser)
						
	Version:	  	            <_>	  		  	Valid from:	  	            <Date>	  	

 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Quality Assurance Agreement 

Between VIEWRAY and SIEMENS 
  

	4.3	Exchange of Quality-relevant information via E-mail 

 For the exchange of quality-relevant information
between the PARTIES via e-mail an appropriate software for the digital signature and encryption shall be used. After this agreement comes into force, the SELLER and BUYER shall mutually determine the software to be used (with the current encryption
standard PGD or S/MIME) and exchange the necessary public keys. 

  

											
	Initials:	  	  
	  	  
	  	Initials:	  	  
	  	  

		  	(Date)	  	(Purchaser)	  		  	(Date)	  	(Purchaser)
						
	Version:	  	            <_>	  		  	Valid from:	  	            <Date>	  	

 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}]]